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“And having seen the multitudes, he was moved with compassion for them, that they were 
faint and cast aside, as sheep not having a shepherd” 
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Title: Neurocognitive Disorders in Young Adults Commencing Highly Active Anti-
retroviral Treatment in the Western Cape 
 
Background 
HIV-associated neurocognitive disorders (HAND) remain prevalent in the era of highly active 
anti-retroviral therapy (HAART). It is not known whether HAND are as prevalent in South 




The published literature was reviewed to elucidate potential mechanisms of the development 
of HIV-associated dementia (HAD)- the most severe form of HAND- and to establish the 
effect that HAART has exerted on HAND across diverse studies. A prospective clinical 
cohort study was initiated in Cape Town, in which 170 participants completed baseline 
clinical and neuropsychological assessments. Laboratory investigations included 
apolipoprotein E (APOE) genotyping. The performance of the International HIV Dementia 
Scale (IHDS) as a brief screening tool was analysed using a receiver operating characteristic 
(ROC). At one-year, 105 participants were re-assessed for neuropsychological change.  
 
Results 
The reviewed literature suggests that HAD is likely mediated by a range of HIV-related 
factors (including possible difference in HIV sub-type) and host-related factors. In addition, 
while neurocognitive improvements are reported in most prospective studies, these are 
dogged by differences in methodology and approach. In this study, 25.4% of participants met 
criteria for HAD at baseline and this was associated with lower levels of education and male 
gender. The APOE4 allelic variant was not associated with those who had developed HAD, 
despite this variant being common in Cape Town. The IHDS performed reasonably well on 
ROC analysis, detecting 86% of dementia cases using a cut-off score of ≤11. At one-year 
follow-up, participants had improved significantly on neuropsychological assessment, 
including a small sub-sample who had not initiated HAART. Significant associated factors 




HAND- including HAD- are common conditions in South Africa, where HIV clade C is 
predominant. Further work to identify cases and delineate mechanisms of disease and 
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treatment response is needed. This might take the form of larger prospective studies, 
incorporating control groups. Such studies could better elucidate disease mechanisms with a 




Glossary of Terms 
 
American Academy of Neurology (AAN) 
Anti-retroviral treatment (ART) 
Apolipoprotein E (APOE) 
Asymptomatic neurocognitive impairment (ANI) 
Alcohol Use Disorders Identification Test (AUDIT) 
Centers for Epidemiological Study- Depression scale (CES-D) 
Composite z-score based on combinations of neuropsychological tests (NPZ) 
Combination anti-retroviral treatment (CART)- same as “Highly active anti-retroviral therapy” 
(HAART) 
CNS Penetration Effectiveness (CPE) 
Immune Reconstitution Inflammatory Syndrome (IRIS) 
Human immuno-deficiency virus (HIV) 
HIV Dementia Scale (HDS) 
HIV-associated neurocognitive disorders (HAND) 
Highly Active Anti-retroviral Therapy (HAART) 
HIV-associated dementia (HAD)- same as HIV- dementia (HIV-D) 
HIV- dementia (HIV-D) 
Mild neurocognitive disorder (MND)  
Minor cognitive and motor disorder (MCMD) 
International HIV Dementia Scale (IHDS) 
Non-nucleotide reverse transcriptase inhibitors (NNRTI’s) 
Memorial Sloan Kettering staging (MSK) 
Mini International Neuropsychiatric Interview (MINI) 
Patient’s Assessment of Own Functioning ( PAOFI) 
People living with HIV/AIDS (PLWHA) 
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Chapter 1.  
 
Introduction 




Human immuno-deficiency virus (HIV) infection constitutes a global pandemic with 
approximately 50 million HIV-positive people worldwide [1]. The majority of people 
infected with HIV live in sub-Saharan Africa and South Africa bears the burden of having 
the largest number of HIV-infected individuals in the world. According to data gathered 
during the National HIV and Syphilis Antenatal Sero-prevalence Survey in 2008, the 
national rate of HIV infection in South Africa was 29.3% [2]. The Western Cape reported 
the lowest estimate of 16.1%. In 2009, 500 000 people were newly infected with HIV in 
South Africa [2].  
 
HIV infects the brain early in the course of infection [3]. A range of neurological and 
psychiatric sequelae follow neuro-invasion. Psychological distress and psychiatric disorders 
are the result of a combination of biological and psycho-social factors. Psychiatric disorders 
in people living with HIV/AIDS (PLWHA) are not only more common, but they exert a 
significant effect on many health-related outcomes. PLWHA are more likely to suffer from a 
mental disorder than the general population [4-7]. Mental disorders, such as depression 
have been consistently linked with lowered likelihood of receiving HAART [8,9], poorer 
medication adherence [10-12], and if untreated, greater mortality [13,14]. In addition, mental 
health in HIV-positive populations have been associated with decreased quality of life [15] 
and may increase high-risk behaviours for the further transmission of HIV [16,17] 
 
Neurological involvement in HIV remains prevalent, with as many as 60% of PLWHA going 
on to develop some form of HIV associated neurocognitive disorder (HAND) in their lifetime 
[18] Prior to the widespread use of highly active anti-retroviral therapy (HAART), infection 
with HIV resulted in HIV-associated dementia (HAD) in about 15% of individuals [19] The 
advent of HAART has substantially altered the nature of these disorders, although they 
frequently persist [18,20]. Specifically, HAART has reduced the incidence of HAD, but the 
prevalence appears to be increasing. More recently, efforts to predict response to HAART 
have intensified. In South Africa, PLWHA are only able to access HAART at CD4 cell counts 
<200 cells/ml, unless they are pregnant, co-infected with tuberculosis, or have a stage 4-
defining illness. This means that substantial organ damage may occur before immune-
reconstitution. In the case of the brain, it is unclear how much of this is reversible.  
 
There are other unique aspects of the HIV epidemic, and its relation to brain 
involvement. Firstly, the epidemic in sub-Saharan Africa is predominantly spread by 
sexual- and mainly heterosexual- transmission; secondly, a substantial proportion of 
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those infected are women; and thirdly, there are limited resources for care, and for 
mental health care in particular[1]. From the point of view of the brain and neurocognitive 
disorders, there are questions regarding the HIV subtypes predominant in South Africa, 
and their propensity to cause neuropsychological impairment. The subtypes of HIV-1 are 
distributed differently across the world, and indeed in Africa. These subtypes, or clades, 
differ in a number of respects, including in the sequencing of potentially neurotoxic viral 
proteins, such as the tat (transactivating transcriptor protein). Some studies have 
suggested that clade C tat is less neurotoxic than other clades (such as B) [21]. Clade C 
is highly predominant in South Africa.  
 
Clinic services in South Africa have faced an exponential growth in demand for care. In 
particular, as HAART has become more readily available, the numbers of individuals 
entering care has risen dramatically. Despite the increase in availability of HAART, many 
do not receive it, and AIDS-related mortality remains unacceptably high- nearly 400 000 
PLWHA died from AIDS in South Africa in 2009 [2]. In addition to increasing access to all 
PLWHA who require HAART, other questions remain: how can we prevent irreversible 
neurological brain damage from HIV infection? To what extent does HAART reverse this 
damage? Should we be starting HAART sooner? How can we screen PLWHA for stage 
4 disease who would not otherwise qualify for HAART? Who are those most at risk for 
severe forms of HAND? This thesis is an attempt to address some of these questions.    
 
Research Aims 
Given that the sero-prevalence of HIV is extremely high in South Africa; that PLWHA are at 
risk of developing neurocognitive disorders; and that there are questions about the 
differences in the HIV epidemic in sub-Saharan Africa and the neurological effects of HIV in 
clade C HIV- it is important to begin to understand these issues in our context.  
The overall aim of this thesis is to characterise PLWHA neurocognitive disorders in 
individuals before and one year after commencement of HAART. In particular, this thesis 
aims to study the socio-demographic, clinical and laboratory correlates of HAND in a group 
of patients about to commence HAART, with a view to describing features potentially 
associated with a diagnosis of HIV dementia. Once these patients have commenced 
HAART, the study further aims to follow them up at one year, in order to describe the impact 
of HAART on neuropsychological functions, and variables which may be associated with 
either improvement or deterioration. To date, there have been no published studies of HAND 
in Southern Africa utilising a detailed neuropsychological test battery. There is a paucity of 
work in Africa in general, with differences in methodologies making comparison across 
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regions difficult. Regional differences include the predominance of clade C HIV in South 
Africa, which has been suggested to account for differences in neurocognition. In addition, 
there is a small literature addressing the issue of the effects of HAART on neurocognition, 
with few prospective treatment effect cohort studies. 
 
Overall description of the project 
 This project arose out of the Division of Neuropsychiatry. A need to understand 
neurocognitive problems in PLWHA more fully arose out of our work with colleagues in 
Infectious Diseases. What resulted was the research protocol that forms the basis of this 
thesis. I then obtained funding from three local sources- the National Research Foundation 
Thuthuka programme, the Biological Psyciatry Special Interest Group of the South African 
Society of Psychiatrists, and the Medical Research Council. We began working in three 
primary health care centres, and asked participants to come to Groote Schuur Hospital for 
testing. A graphic representation of the project and how aspects of the work related to 
distinct manuscripts is presented in Figure 1. These manuscripts are what comprise this 
thesis.  
 
Other work and projects have arisen subsequent to this parent project commencing. A small 
number of participants who received neurocognitive and neuromedical testing, were imaged 
at the Cross University Brain Imaging Centre (CUBIC). From this work, two master’s 
students were able to obtain data for the registration and completion of dissertations- Jackie 
Hoare described imaging correlates of neurocognitive disorders in 44 participants; and Celia 
Mahne (under the supervision of Marc Combrinck) described the correlation between 
peripheral blood markers of neuro-inflammation and magnetic resonance spectroscopy. Pilot 
data from the overall project was also instrumental in our group successfully competing for 
an RO1 grant of the National Institutes of Health, with Robert Paul as Principle Investigator. 
 
Neuropsychological testing 
Particular challenges presented themselves regarding neuropsychological assessment of 
this patient group. Specifically, it is not possible to simply administer neuropsychological 
tests that were developed in North America (where most have been developed) into other 
regions of the world.  Rather, significant effort is required to ensure the neuropsychological 
measures are culturally relevant and that the local population understands the task demands 
so that the cognitive measures measure the same brain systems on which they were 
developed to measure. I went about the process of selecting an appropriate battery in 
several ways. First, I met with three local expert neuropsychologists to establish their views 
on how tests needed to be adapted, which brain functions they considered needed to be 
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measured in people living with HIV in our population, and lastly, which measures they 
considered would be appropriate. Second, I met with the study neuropsychologist who had 
been working on a large study of HIV encephalopathy in the Western Cape, and established 
her views on the above matters. Lastly, I reviewed the published literature on the issue of 
international neuropsychological assessment. The battery used in this work was ultimately 
based on that used at the HIV Neurobehavioural Research Center (located at the University 
of California, San Diego). The battery consists of measures now well-established to sample 
the domains of function affected by HIV. It also utilises multiple measure for each of several 
domains of function. Once we had identified the battery, and having considered the opinions 
of local experts, I set about first forwards and back-translating all test instructions. We also 
reviewed word-lists for appropriateness and made changes as needed. For example, we 
switched the “gemstones” list in the Hopkin’s verbal learning test for “vegetables”. Few data 
on the psychometric properties of these tests exist for South Africa. Norms are available for 
Uganda. The work of Anne Shuttleworth Edwards has demonstrated that both the quality 
and level of education of participants may affect test performance. This makes adaption to 
local settings critical. In this regard, early in the course of the study we employed isi-Xhosa 
speaking technicians who were carefully trained and supervised to test study participants. 
The imperative to generate local normative data were paramount, and I set about generating 
these during the course of the study. Completed normative data were not available during 
analysis of these data, but I was able to make use of first 50, then later approximately 100 
demographically matched controls. 
 
Coherence of the thesis 
The coherence of this thesis revolves around three main points. Firstly, the thesis centres 
around my own role as the single principle investigator. In this respect, I initiated and led the 
project from conception to completion. Secondly, the thesis involves a single project. Each 
chapter describes an analysis conducted on the same cohort of patients enrolled into this 
study. Thirdly, there is a distinctly unifying theme to this thesis, namely, how neurocognitive 
disorders may vary between individuals and over time in PLWHA, and the impact of a 
number of variables, including HAART, on these disorders. This thesis has therefore 
resulted in a series of manuscripts, of which four have been published to date. They 
represent an evolution in the work.  
 
I have included two review papers (chapters 2 and 3). The first, currently in press, provides a 
theoretical overview of the neurobiology of HIV-dementia, and how this might be relevant to 
PLWHA in South Africa. The issue of clade diversity has been brought to the fore in this 
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piece. The second review is systematic, and has been published. This piece examines in 
more detail how HAART might impact on neurocognitive disorders over time. This review 
also highlights how disparate research methodologies might affect our understanding of 
these conditions across different research settings.  
 
In chapter 4, I seek to describe the prevalence and associated features of HAND in primary 
health care settings in Cape Town. It is not known whether clade C HIV produces similar 
rates of HAND as in North America and Europe. Also, the effect of socio-demographic, 
nutritional and related laboratory measures is not known.  The relationship between the 
development of HIV-associated dementia (HAD) and the apolipoprotein E (APOE) allelic 
variant has been reported in studies in North America with differing results. I sought to 
describe the prevalence of the APOE genotype and its association with HAD in this 
population (chapter 6). The importance of screening for HIV-dementia has been emphasised 
above. In this regard, I investigated in chapter 6 whether the International HIV Dementia 
Scale (IHDS) performs adequately in our setting, in a receiver operating curve analysis. The 
last chapter (7) seeks to investigate whether the use of HAART was associated with 
improvement in neuropsychological function. Studies to date have generally reported 
significant improvements, but there is a paucity of prospective studies, and none have been 
conducted in Southern Africa.  
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Figure 1. Outline of study and project process and manuscript preparation and publication 
Timeline      Process       Manuscripts 
Loss to follow-up: 
Deceased= 9 
Migrated= 6 
Loss to Follow-up= 33 
Unknown= 8 
Chapter 6. “Screening for HIV Dementia using the 
International HIV Dementia Scale in South Africa” 
 
Chapter 5. Association between apolipoprotein E4 
genotype and human immunodeficiency virus-
associated dementia in younger adults starting 
antiretroviral therapy in South Africa 
Chapter 4. “Characterisation of HIV-associated 
Neurocognitive Disorders Among Individuals 
Starting Anti-retroviral therapy in South 
Africa”Baseline assessments   n=170 
Chapter 3. Review: “Does Highly Active Anti-
retroviral therapy improve neurocognition: A 
systematic review” 
Chapter 7. “Neuropsychological outcomes in 
young adults commencing anti-retroviral 
treatment in South Africa” 
Chapter 2. Review: “The Neurobiology of HIV-
dementia: Implications for practice in South Africa 
Follow-up 




Genotyping;      
IHDS screening 
Baseline 






March 2008 to 
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In this review, the neuropathogenesis of HIV dementia (HIV-D) is discussed in the 
context of the local epidemic in SA. HIV-D continues to be prevalent in the era of 
highly active anti-retroviral therapy. HIV neuro-invasion into the central nervous 
system may result in the development of separate HIV genotypes in an individual 
through compartmentalisation. The blood brain barrier continues to limit penetration 
of anti-retroviral drugs into the cerebrospinal fluid. Individuals with active neuro-
inflammation appear to respond well to HAART. In some cases low grade neuro-
degeneration persists with consequent clinical deterioration. In South Africa, the 
emergence of a sub-epidemic of HIV-D is being driven by various factors, including 
the incomplete coverage of HAART to all who need it, the late stage presentation of 
people living with HIV/AIDS (PLWHA) and a co-occurring methamphetamine 
epidemic. Differences in viral subtype do not appear to confer protection against HIV-
D. Implications for PLWHA who are at risk for HIV-D in South Africa are explored, 





Infection with human immuno-deficiency virus type 1 (HIV) is an important health 
concern globally but especially in South Africa, which has the highest number of 
people living with HIV/AIDS (PLWHA) [1]. HIV is known to cause adverse 
neurological sequelae (also known as “neuroAIDS”) in a substantial proportion of 
individuals. Despite improved survival and quality of life following the use of highly 
active anti-retroviral therapy (HAART), neuroAIDS remains prevalent. In this review, 
we describe the neurobiology of dementia associated with HIV. In particular, we 
describe the process of neuroinvasion, subsequent neurodegeneration and 
treatments. We further aim to address how the sub-epidemic of neuroAIDS may 
impact individuals and services in South Africa and suggest strategies for 
approaching this problem.  
 
NeuroAIDS remains prevalent, with as many as 60% of PLWHA going on to develop 
some form of HIV associated neurocognitive disorder (HAND) in their lifetime [2]. 
Furthermore nearly 90% of individuals have autopsy evidence of neuropathology. 
Neuro-invasion is likely to occur early in the course of HIV infection following 
dissemination of HIV into lymphoid tissues and cells [3]. The blood brain barrier not 
only limits ongoing passage of HIV into the central nervous system (CNS) following 
this early peak in viral load, but also acts as a barrier to drug penetration [4]. The 
active infection of CNS microglial cells results in the development of a neurotoxic 
inflammatory cascade, which involves primarily the sub-cortical white matter and 
striatum [5]. Neurocognitive dysfunction follows the disruption of these circuits, while 
neuronal apoptosis produces cortical atrophy [6]. Early response to HAART is 
probably associated with a rapid suppression of acute neuro-inflammation (an 
“encephalopathy” syndrome), while delayed improvement may occur following 
immune reconstitution and restoration of white matter [7]. 
 
Numerous clinical variables are now known to be associated with the development of 
HIV-D, including low CD4 cell count and late stage disease [7]. These are especially 
relevant in South Africa where the epidemic is greatest and HAART coverage is yet 
incomplete. The abuse of methamphetamine not only increases HIV risk behaviour, 
but is independently associated with neurotoxicity [8,9]. While the use of HAART has 
resulted in a dramatic reduction in the incidence of HIV-D, PLWHA with milder HAND 
do not qualify for treatment. Mild neurocognitive disorder may  be a predictor of HIV-
D, or at least is associated with neuropathological changes of HIV encephalitis [10]. 
Non-HAART treatments including the use of lithium and memantine have been 
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studied but results are not robust enough to warrant widespread use [8,11]. In a 
resource-limited setting such as South Africa, broad screening for HIV-D should be 
routine, and the use of HAART in PLWHA who have demonstrable neurocognitive 
disorder should be strongly considered. The implications at an individual, community 
and societal level of untreated or persistent neurocognitive disorders in large 
numbers of individuals are substantial. 
 
Prevalence of HIV dementia: Epidemiology and challenges 
HAND remains prevalent despite HAART and clinical characteristics may be 
different. Prior to the widespread use of HAART, infection with HIV resulted in HIV-D 
in about 15% of individuals [12]. Less severe forms of HAND were found in about 30-
60% of PLWHA [12,13]. The advent of HAART has substantially altered the nature of 
these disorders, although they do persist [2,14]. Specifically, HAART has reduced the 
incidence of HIV-D, but with longer life span, the prevalence appears to be increasing 
[7,15]. Not only does this persistence suggest either ongoing neurotoxocity, but it has 
implications for PLWHA who may be employed and/or need to adhere to HAART. In 
addition, the clinical presentation of HIV-D has changed [6], and it has been 
suggested that the subcortical features previously thought to be characteristic, may 
be less prominent [16]. As experience in the neuropsychological features of HAND 
has grown, it has become more apparent that cortical deficits occur frequently.  
 
More recently, efforts to predict the neurocognitive response to HAART have 
intensified. Currently it is thought that people who initiate HAART prior to severe 
immunosuppression and achieve plasma viral suppression [17], CSF viral 
suppression [4] and who use CSF penetrating regimens accrue the most benefit 
[4,18]. In South Africa, home to the largest number of PLWHA, and despite one of 
the biggest anti-retroviral rollout programmes internationally, PLWHA still enter 
treatment late, if at all. Reasons include limited access to HAART, confusing 
government and media messaging regarding treatment, and socio-cultural issues 
(such as belief systems regarding the causes of HIV). Accordingly, the profile of this 
group of individuals resembles a pre-HAART cohort, with a high incidence of HIV-D. 
The only local study of community prevalence of HIV-D, conducted in the Western 
Cape reported a rate of 23.5% of HIV-D according to the HIV Dementia Scale [19]. 
This compares to the rate found in a study in Uganda, where the prevalence was 




In addition to the lateness of presentation of PLWHA, clade-specific differences may 
contribute to the development of HAND. HIV subtype (or clade) B is predominant in 
North America and Europe, while clade C is found in about 90% of South Africans 
[21,22]. The question of whether viral clade is responsible for differences in HAND 
has not been well-studied in clinical populations. For instance, the neurovirulence of 
HIV clade C has been associated with less severe forms of neurocognitive 
impairment in some studies, but with equally deleterious effects in others [23-25]. 
Variability has been attributed to differences in the dicysteine motif within the 
neurotoxic region of B-Tat, producing a greater degree of Tat-induced apoptosis 
[26,27]. However, other viral proteins, such as gp120, may be as neurotoxic. The 
clade sequence, levels of proviral DNA and tat protein, together with their impact on 
neuropsychological functions and neuro-imaging findings, is the subject of a study 
currently being conducted by our group.  
 
Neuro-invasion and compartmentalisation 
Neuro-invasion probably occurs early in HIV infection, and is associated with 
dissemination of HIV into lymphoid tissues, which include the CD4 helper cells and 
circulating monocytes [3]. All five main types of cell in the CNS are susceptible to the 
effects of infection, but it is thought that only perivascular macrophages and microglia 
are actively or productively infected [28]. These cells are derived from bone marrow. 
Both are immune-competent in the CNS, with microglia arising from the mesoderm- 
as such they bear receptors related to the mononuclear phagocytic system [29]. In 
the resting state they are branched, while in the activated state, they are rounded or 
“amoeboid” [28]. Active or productive infection implies that HIV is constantly being 
produced from the cell surface, while non-productive infection implies that HIV DNA 
is incorporated into host cell, but not actively extruded. This latter type of infection, 
together with the restricted nature of the blood-brain barrier has led to the idea that 
the CNS is a “sanctuary” site or reservoir of HIV infection. The blood brain barrier is a 
selectively permeable membrane formed by a continuous cellular barrier with tight 
junctions. The passage of circulating immuno-competent cells into the CSF is tightly 
regulated, as is that of drugs.  
 
A number of theories of neuro-invasion have been proposed, but it seems likely that 
the majority of invasion arises from the passage of HIV inside penetrating circulating 
macrophages (“Trojan Horse theory”) and from transcytosis- a process of HIV being 
actively transported through endothelial cells [30]. Perivascular macrophages are 
probably the cell line most infected and are also readily replenished from the 
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circulating peripheral population [31]. These cells, together with some microglia, fuse 
to make up the multi-nucleated giant cells (MNGC) which are the hallmark of HIV-
encephalitis [28]. HIV encephalitis is the underlying neuropathological correlate of 
HIV-D. MNGC express CD14 and CD15 receptors, and these are noted on 
neuropathological examinations [32]. 
 
Following early CNS invasion, HIV probably re-enters the CNS throughout the course 
of infection during periods of either high viral load or systemic illness [28]. Despite 
this, phylogenetic reconstruction has suggested that HIV derived from various sites in 
the CNS in an individual more closely resembles its own sequences, than HIV 
derived from peripheral tissues [33]. In addition, unproductive infection of cell lines 
other than microglia and macrophages suggests that genetic drift of HIV may be 
small. These ideas again have led credence to the notion of the CNS as a sanctuary 
site. 
 
While most PLWHA have evidence of neuroAIDS, few will develop frank clinical 
features. This might be explained by certain host factors (such as genetic 
predisposition) and the differing neuropathogenicity of HIV. One possible mechanism 
is differing “fusogenic” potential. In the CNS, cells bearing the chemokine receptor 
CCR5, as well as CD4, are prone to being fused into MNGC. Highly neuropathogenic 
forms of HIV might require lower levels of expression of these proteins, possibly 
leading to more rapid and/or greater MNGC formation [34]. Furthermore, certain HIV 
strains might evolve into separately neuropathogenic strains through the 
development of envelope glycoproteins which lower the need for host CCR5 and 
CD4 receptors.  
 
There has been conflicting data on whether the viral load of HIV in the CSF (as 
opposed to the periphery) is associated with greater rates of HAND. Some studies 
have established that improvement in neuropsychological function is correlated with 
both high CNS penetration of HAART, as well as lower CSF viral loads [4]. A more 
recent study reported that while penetrating HAART regimens were correlated with 
lower CSF viral loads, these regimens resulted in poorer neuropsychological 
performance [35]. The relevance of the penetration of anti-retrovirals is explained 
below. It must be noted that in the public sector in South Africa, there is access to 
only a limited number of these agents.  
 
Mechanisms of neuro-degeneration 
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Neurodegeneration follows a breakdown in the usual interplay between 
neuroprotection and neurotoxicity. These involve interactions between various 
protective and toxic host compounds (such as nerve growth factors and glutamate) 
and the effect of the inflammatory process invoked by HIV. An understanding of the 
role of CNS chemokines and neurotransmitters has begun to shed light on possible 
mechanisms of HIV neurotoxicity. Chemokines are cellular cytokines secreted in the 
CNS and which play various roles including cell migration, differentiation, activation 
and proliferation. These processes are constantly occurring. Two main families of 
chemokines are especially relevant to HIV: α- and β-chemokines [28]. α-chemokines 
(also known as CXC family chemokines) are all expressed in brain, mainly by 
neurons. The activated CXC receptor increases intra-cellular calcium, and may be 
key to excitotoxic damage [36]. In contrast, β- chemokines (CCR family chemokines) 
are only weakly expressed in brain. Despite being weakly expressed, certain β- 
chemokines play a crucial role in the development of HAND- these include monocyte 
chemoattractant protein-1 (MCP-1). Higher levels are thought to predict HIV-D over 
time [7]. Other members of the β- chemokine group may be neuroprotective, such as 
CCL4, which protects neurons from gp120 induced apoptosis [36]. It can then be 
seen that when HIV infects and activates CD14/16 bearing cells, pro-inflammatory 
cytokines are increased, leading to the development of both MNGC and related glial 
and neuronal cell damage. 
 
Two main theories of HIV-associated neurodegeneration have been proposed. The 
direct injury hypothesis posits that neuronal injury occurs directly through the effect of 
toxic HIV proteins - gp120 and tat protein in particular - or through virus-host 
interactions, whereby gp120 activates glutamate receptors or TNF expression [37]. In 
the “bystander” effect hypothesis, damage occurs due to immune activation out of 
keeping with levels of HIV in the CNS. This amplification arises out of chemokine 
activation, the inflammatory activation of uninfected cells and the migration of 
infected T-cells into the CNS following chemo-attraction [38].  
 
The result of either direct or bystander effects is the neuropathological entity known 
as HIV encephalitis. This entity is now established to underlie well defined clinical 
HIV-D [10,39]. In this process, the activation of inflammatory chemokines and 
cytokines, including TNF and nitric oxide synthase, leads to the production of free 
radicals, which in turn leads to astrocyte apoptosis [40]. Astrocytes play a key role in 
the removal of excitatory amino acids from synapses, leading to a loss of the 
neuroprotection/neurodegeneration balance. High levels of inflammation and 
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neurotransmitter dysregluation may lead to clinical features of “encephalopathy”, 
while neuronal apoptosis and degradation of white matter may lead to less reversible 
deficits characterised by clinical slowing and subcortical effects. 
 
The role of transcriptional transactivator (tat), a toxic viral protein bears mention. Tat 
has been associated with neuronal nuclear toxicity, alteration of blood brain barrier 
tight junctions and the upregulation of pro-inflammatory cytokines [41]. It has been 
found that tat expression differs between HIV clades, and further proposed that a 
defect in the dicysteine motif in tat in clade C leads to lower levels of neurotoxicity 
[42]. The implications are that in regions where clade C is predominant, such as 
South Africa, lower rates of HAND might be expected. Recent work in India, where 
clade C is also predominant has not supported this idea. Rates of HAND comparable 
to regions where clade B occurs, was reported in a clinical sample [43]. A large study 
into potential clade differences is underway by our group.  
 
Clinical mediators of HIV dementia 
A number of clinical factors are associated with the development of HIV-D, and are 
reviewed in this section, with a particular focus on their relevance to SA. These 
include the presence of neurological impairment, the abuse of methamphetamine, 
depression, female gender, low CD4 count and advancing age [7,44-46]. 
 
Substance abuse and dependence are linked to both the acquisition of HIV, as well 
as to compounded neurocognitive effects. The use of intravenous opiates, especially 
heroin has been associated with the epidemic in North America, and to the co-
infection with hepatitis C. In South Africa, heroin use is fairly restricted, although it 
has the potential to grow [47]. In addition, hepatitis C is thought to be very 
uncommon in South Africa, as reported by one published study in Kwazulu Natal 
[48]. The effect of methamphetamine (MA) on both HIV risk behaviour and 
neuropsychological outcomes is increasingly being studied, and is of especial 
relevance locally. In a sample of more than 4500 adolescents at Cape Town schools, 
12-13% had used MA at least once, and MA was associated with high risk sexual 
behaviour [9]. There is now good evidence for the deleterious effect of MA on 
neuropsychological function [49]. It has been proposed that when MA abuse and HIV 
co-exist, additive neurotoxic effects, such as increased ischaemic events and 
microglial activity may occur [8].The implications for South Africa where MA abuse is 




Also of relevance to South Africa, is that the majority of PLWHA attending clinics are 
women, and again, that many present with late stage HIV/AIDS. The preponderance 
of women is a feature that differentiates the Southern African epidemic from the 
global one. There are some well known gender effects in neuropsychiatry, with 
depression being more common in women [50]. As depression is commonly co-
morbid with HAND, a greater burden of disease in South Africa might be expected. 
There is also substantial evidence that advancing age is associated with a greater 
vulnerability to developing HAND, and that this may be aggravated by the use of 
protease inhibitor containing regimens [8]. As with persons with Alzheimer’s 
dementia, the amyloid protein has been implicated. Specifically, high levels of β-
amyloid have been observed in HIV neuropathology, as well as increases in amyloid 
precursor protein and gamma secretase. Tat may inhibit an amyloid degrading 
enzyme [8]. With the largest HIV epidemic in the world, and the accordingly large 
numbers of PLWHA entering treatment, we will face an ageing population with these 
co-factors.  
 
Pharmacotherapy of HIV-D 
Conceptually, the approach to treatment of HIV-D could be considered from either a 
preventive or curative view. Drug treatments can then be considered to be either 
directly anti-retroviral, or adjuvant. Current WHO guidelines recommend the use of 
HAART when either CD4 cell counts fall below 200, or a stage 4 disease-defining 
illness is present. Among these conditions is HIV encephalopathy. Once HIV-D is 
established, it may be difficult to reverse neuronal loss. This raises two central issues 
regarding the treatment of HIV-D: first, whether the brain is a long term reservoir of 
HIV, and therefore if ongoing low grade neuro-inflammation is occurring; and second, 
whether less severe forms of HAND either predict or progress to HIV-D. We will now 
address each of these issues. 
 
First, regarding whether the brain is a reservoir for HIV, there has been much interest 
in the issue of the penetration of antiretrovirals through the blood brain barrier. The 
ability of these agents to pass into the brain, depending on their protein-binding, 
molecular size and lipophilicity has been categorised into a “CNS Penetration 
Effectiveness” (CPE) rank system [51]. In this system, anti-retroviral drugs are 
categorised into groups according to the above criteria, with scores of 0.5, 1 and 2 
being assigned to the three groups. The nucleotide/nucleoside reverse transcriptase 
inhibitors lamivudine and stavudine, for example, have a rank score of 0.5. Of the 
non-nucleotide/nucleoside reverse transcriptase inhibitors, nevirapine has a score of 
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1 and efavirenz 0.5. These drugs are the first line treatments in South Africa. While 
several studies have shown that regimens with a relatively high CPE rank (>2) 
resulted in better neurocognitive outcomes [4], it is not well known whether these 
regimens may produce neurotoxicity by virtue of their penetration, whether the 
benefits will persist, or if the HAART-related improvements to date have been 
observed in individuals with poor baseline neuropsychological performance or worse 
levels of immunosuppression. Long term studies which examine both the 
neurocognitive profile, CPE rank, as well as potential measures of antiretroviral 
neurotoxicity will be needed to resolve these issues. In a well known study, the 
addition of abacavir to an existing HAART regimen was not associated with improved 
neurocognitive outcomes [7]. First line treatments in South Africa achieve acceptable 
CPE ranks scores of between 1.5 and 2. Using a nevirapine-based regimen, a score 
of 2 is reached by adding the rank scores of lamivudine (0.5), stavudine (0.5) and 
nevirapine (1).  
 
Second, whether or not less severe forms of HAND result in, or progress to HIV-D, 
are less clear. Different patterns of HIV-D have now been proposed [15]. It is 
suggested that some more acute and fulminant forms may be more sensitive to 
treatments. Nonetheless, only a small proportion of individuals will recover complete 
neuropsychological function. If, however, HAART could be initiated at higher CD4 
counts, where less severe HAND is present, it is possible that progression to less 
reversible deficits may be prevented. Once HIV-D is present, effective HAART 
regimens should be used in the first instance. Prospective studies of these issues are 
sorely needed.  
 
The issue of antiretroviral toxicity has been addressed to a limited extent in the 
literature, and is based on theories of systemic toxicity, scanty magnetic resonance 
imaging (MRS) studies, and in vitro evidence [52-54]. This type of antiretroviral 
neurotoxicity is independent of the phenomenon of neuroIRIS (immune reconstitution 
syndrome), which is thought to be rare but may result in worsening neurocognitive 
function despite HAART use [55]. NeuroIRIS may occur from between two and six 
weeks of HAART, and reflects an inflammatory response following cellular immune 
reactivation. IRIS is most consistently associated with opportunistic infections (OI’s), 
such as Cryptococcus, tuberculosis or JC-virus. In a small number of individuals, 
clinical neurological deterioration occurs in the absence of OI’s, and is thought to 




Adjuvant treatments for HIV-D are less well established. Treatment trials of known 
drugs such as memantine, an N-methyl-D-asparate (NMDA) receptor antagonist, and 
lithium, a complex mood stabiliser with glycogen synthase kinase-3 (GSK-3) function, 
have been conducted with some promising results [11,56]. While lithium may not be 
an ideal agent in South Africa, and particularly in PLWHA, due its narrow therapeutic 
index, its beneficial effects may be considered as therapeutic possibilities for other 
drugs. Putative treatments, based on theories of HIV neurotoxicity include chemokine 
receptor blockers, anti-oxidants, caspase inhibitors and entry inhibitors, but any novel 
agent would need to penetrate the blood brain barrier.  
 
Outcomes in HIV-D 
The effective use of HAART has clearly been associated with a significant reduction 
in the disease burden of HIV-D, as noted above. The incidence of HIV-D has 
decreased substantially [7]. In untreated HIV-D the mean survival is about six months 
[57]. With HAART, this has increased to two years, even in PLWHA with low CD4 
counts at baseline [58]. Given that more than 20% of individuals in primary care in 
the Western Cape have HIV-D, there are significant implications for care [19].  
 
Nath and colleagues have proposed a number of subtypes of HIV-D that have 
emerged in the HAART era, including a subacute progressive type, a chronic inactive 
type, a chronic active type and a reversible type [15]. Other groups have reported 
“reversibility” or “treatment response” in about 30% of PLWHA with HIV-D [59]. The 
converse is true that more than half have persistent deficits. This means that on the 
one hand, a substantial number of PLHWA with HIV-D will improve, and that the use 
of HAART is imperative, but also that a larger number will require additional 
treatment support. The implications for PLWHA who are economically or socially 
active are enormous. To date, there are no published cohort studies in South Africa, 
and this is needed.  
 
Approaches to detection, treatment and research in resource-limited settings 
Given that South Africa has the largest HIV epidemic in the world, and that despite 
putative clade differences in neurotoxicity, it is likely that a substantial proportion of 
individuals entering late stage HIV/AIDS will develop HIV-D. Our approach should be 
three-fold: 
 
(1) Wide-spread screening programmes: 
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This will involve the use of screening tools for HIV-D being integrated into primary 
health care. This is in order to detect covert cases of HIV-D in busy clinics, where 
awareness of milder HIV-D may be low. Several instruments exist, including the HIV 
Dementia Scale and the Brief Cognitive Neuroscreen [60,61]. A brief tool that has 
been validated for use in Uganda, and that can be taught to non-neurologist staff, is 
the International HIV Dementia Scale (IHDS) [62]. Using a cut-off score of 10, the 
IHDS has a sensitivity and specificity of 80% and 55% respectively. The integration 
of the IHDS will involve training in its use, and information regarding what to do with 
positive screens. At clinics, where more extensive neuropsychological testing is not 
available, patients who screen positive may be evaluated by more experienced 
clinicians on a referral basis, and then initiated on HAART. Additional treatment 
support and follow-up should be considered. Where additional neuropsychological 
resources are available, referral may be an option. We recommend the use of a test 
battery containing tests of the following domains: attention and concentration, verbal 
memory, psychomotor function and executive function. Tests within these domains 
may include the digit symbol coding test for attention, the Hopkins auditory verbal 
learning test for verbal memory, the grooved pegboard test for psychomotor speed, 
and the color trails tests 1 and 2 for executive function. These tests are widely used 
and are readily taught to technical staff with a minimum of necessary equipment. 
 
(2) Consideration of offering HAART to individuals with higher CD4 counts  
There is debate as to whether HAART should be started in PLWHA with higher CD4 
counts. What is known, is firstly, that mild neurocognitive disorders (MND) are 
common, occurring in about 20-30% of PLWHA, depending on disease stage [13]. 
Secondly, the presence of MND correlates with neuropathological changes similar to 
HIV-D [39]. Thirdly, the presence of MND is likely to produce significant functional 
impairment [63]. Whether or not MND predicts progression to HIV-D is less clear. We 
propose that PLWHA with documented MND and functional impairment are at risk of 
this deterioration, and should be initiated on HAART. Prospective cohort studies are 
needed to define the outcomes more clearly. 
 
(3) Prospective cohort treatment effects studies 
To date, there have been no published cohort treatment effect studies in South 
Africa, and relatively few in Africa. Studies of PLWHA entering ARV care should be 
conducted with a view to describing the course and progression of 
neuropsychological impairment, the impact on function, and the effect of anti-
retrovirals on cognition. Careful clinical characterisation may further allow for the 
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development of predictive variables and potential biomarkers of HIV-D. In this way, a 
greater understanding of potential risk factors may be developed. The effect of anti-
retrovirals on cognition is receiving greater attention and these studies should 
carefully document these [15].  
 
Conclusion 
The involvement of the CNS in HIV- known as “neuroAIDS”- has profound 
implications in South Africa where the largest number of infected people lives. 
Several clinical implications emerge from this review. Screening for HAND should be 
routinely performed in all individuals entering care, and in those with higher CD4 
counts in whom a neurocognitive disorder is suspected. They should be followed up 
in order to describe the course and impact of neuroAIDS. In this way, we can begin 
to address the massive burden that dementia-associated with HIV infection poses. 
 
Locally relevant research directions should include investigations into either 
“mechanisms” or “treatments”. Prospective cohorts in South Africa should be studied, 
with a view to gathering not only data on neurocognitive problems and their course, 
but also the underlying host-viral interactions, such as clade-specific differences. 
Treatment programme research needs to consider ways of addressing the burden of 
disease of neurocognitive disorders, and may involve studies of epidemiology, but 
also of providing supportive and therapeutic approaches to individuals with 
neurocognitive problems. The problem of HIV dementia will not abate with 
widespread HAART, and novel solutions to address this burden are urgently needed.  
 
There is an a priori assumption that HAART improves neurocognitive function, 
following immune-reconstitution. Prospective empiric studies need to be reviewed to 
document this outcome. In particular, questions remain as to the extent that HAART 
improves neurocognition; whether some domains of function improve more than 
others; and whether or not response to HAART can be predicted based on 
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 Highly active anti-retroviral therapy (HAART) reduces the incidence of HIV-dementia 
(HAD), while the overall prevalence appears to have increased. Recent changes to 
diagnostic nosology have emphasised the presence of neurocognitive deficits. 
Uniform methods of ascertaining neuropsychological impairment and excluding 
confounding causes are critical to between-study comparison. We conducted a 
systematic review on all studies which use single cohort prospective treatment effect 
design that reported on the neurocognitive or neuropsychological profile of 
individuals commencing HAART. We included 15 relevant studies. A large number of 
studies using observational or cross-sectional designs were excluded, as these do 
not allow for a within-subject description of pre- and post-HAART predictive factors. 
Eleven studies reported a significant improvement in neurocognitive status or 
neuropsychological profile over an average study period of six months. Variable or 
non-reporting of HAART regimens in these studies did not allow for an analysis of 
individual agent or regimen effectiveness.  While HAART does improve cognition, it 
does not appear to fully eradicate impairments. The methods used in this research 
differ widely and therefore comparison across studies is difficult. Studies examining 
the long term effects of HAART on HIV-associated neurocognitive disorders (HAND) 
using uniform methods of data collection are needed, together with clear reporting of 




 Prior to the widespread use of highly active anti-retroviral therapy (HAART), infection 
with HIV resulted in HIV-associated dementia (HAD) in about 15% of individuals [1]. 
Less severe forms of HIV-associated neurocognitive disorders (HAND) are found in 
about 30-60% of people living with HIV/AIDS [1,2]. The advent of HAART has 
substantially altered the nature of these disorders, although they frequently persist 
[3,4]. Specifically, HAART has reduced the incidence of HAD, but the prevalence 
appears to be increasing [5,6]. In addition, the clinical presentation of HAD has 
changed [7]. It has been suggested that the sub-cortical features previously thought 
to be characteristic, may be less prominent [8]. More recently, efforts to predict 
response to HAART have intensified. Currently it is thought that people who initiate 
HAART and achieve plasma viral suppression [9], CSF viral suppression [10] and 
who use CSF penetrating regimens accrue the most benefit [10,11].   
 
Central to the characterisation and description of HAND is the use of a universal 
diagnostic classification. The original criteria of the American Academy of Neurology, 
proposed in 1991, recognised two main forms: that of HAD, and a less severe minor 
cognitive and motor disorder (MCMD) [12]. This system emphasised the presence of 
behavioural and personality changes. The limitations of this approach, particularly in 
the face of both a growing understanding of HAND and the use of HAART, include a 
lack of emphasis on the cognitive deficits in HIV, as well as the presence of these 
deficits in the absence of overt functional decline in some individuals [13]. These 
limitations were addressed in a set of newer research criteria, proposed by the HIV 
Neurobehavioural Research Center (HNRC) and published in 2007 [14]. They now 
include a category of asymptomatic neurocognitive impairment (ANI), and also 
address the more widespread neurocognitive deficits which are thought to occur in 
HIV. The ANI category together with mild neurocognitive disorder (MND), require that 
neuropsychological deficits corresponding to at least one standard deviation below 
age-appropriate norms in at least two cognitive domains exist. A diagnosis of HAD is 
made when two or more domains reveal deficits of at least two standard deviations 
below the norm [15]. In addition, other causes of cognitive disorder need to be 
excluded, and some measure of function must be provided. Widespread use of this 
approach would go a long way to standardise studies of HAND, but may not always 
be possible or practical, particularly in resource-limited settings.  
These clinical case definitions are now known to represent the underlying 
neuropathology, namely HIV encephalitis, and demonstrate a sensitivity and 
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specificity of 67% and 92%, respectively, for the HNRC categories [16,16,17]. As 
indicated above, these neuro-pathological changes are now thought to involve 
various cognitive domains. In fact, if systemic disease factors are controlled for, HAD 
is characterised by severe deficits in learning, motor coordination, verbal fluency, and 
memory, while moderate deficits are observed in attention and processing speed 
[18]. These represent a range of deficits across subcortical and cortical domains. In 
order to ascertain whether neuropsychological deficits are indeed related  to HIV-
related neuropathology, it is therefore necessary to assemble a range of 
neuropsychological tests that measure the brain regions thought to be typically 
affected by HIV [4]. Clinical and research batteries differ widely in their selection of 
tests, duration and spread across cognitive domains.  
Other factors which impact on HAART-related outcomes include study design, 
longitudinal construct validity of neuropsychological testing, and numerous treatment 
and disease variables. In a recent substantive review, Cysique and Brew clearly 
delineate differences between cross-sectional cohort designed studies, prospective 
observational cohort studies and prospective treatment effect studies [19]. The cross-
sectional studies are largely limited by uncontrolled cohort effects (see [3,20], while 
the prospective observational studies tend to include cohorts already on HAART who 
have either switched regimens or followed neuropsychological changes whilst on 
HAART (see [21,22]. Prospective treatment effect cohort studies offer the advantage 
of describing a range of pre-treatment variables, which may either predict or be 
associated with positive or adverse outcomes. These are then carried into the study 
in a case-controlled manner. The issue of longitudinal construct validity refers to 
whether tests or sub-tests can be considered appropriate for measuring 
neuropsychological functions over time. It is possible that some functions may 
improve de facto, but that change over time may also be affected by the specific 
function reaching a plateau due to persistence of deficits, practice effects, the 
severity of the deficit at baseline or disease-specific factors [23-25].  
Disease-specific factors which may impact on outcomes in HAND include viral 
resistance, HAART-related neurotoxicity, central nervous system (CNS) penetration 
of HAART, the effects of ageing and co-morbidities, viral clade, and molecular 
biology. In particular, it is well established that HAART has reduced the incidence of 
severe forms of HAND, such as HAD, while there is clear evidence that at least 
milder forms persist (see [3,26]. Viral resistance may follow individual non-adherence 
and systemic resistance, the infection of individuals with resistant strains of virus, or 
the development of intra-individual (CNS in particular) resistance [27,28]. CNS 
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compartment resistance, whereby the CNS acts like a reservoir of HIV, may be 
affected by limited or even differential penetration of individual anti-retroviral drugs 
(see below) [29]. The issue of anti-retroviral toxicity has been addressed to a limited 
extent in the literature, and is based on theories of systemic toxicity, scanty MRS 
studies, and in vitro evidence [30-32]. This type of anti-retroviral neurotoxicity is 
independent of the phenomenon of neuroIRIS (immune reconstitution inflammatory 
syndrome), which is thought to be rare but may result in worsening neurocognitive 
function despite HAART use [33].  
A related factor is the penetration of anti-retrovirals through the blood-brain barrier. 
The ability of these agents to pass into the brain, depending on their protein-binding, 
molecular size and lipophilicity has led to the development of a “CNS Penetration 
Effectiveness” (CPE) rank system [34]. While several studies have shown that 
regimens with a relatively high CPE rank (>2) resulted in better neurocognitive 
outcomes (see Letendre et al., 2004; [10], it is not well known whether these 
regimens may produce neurotoxicity, whether the benefits will persist, or if the 
HAART-related improvements to date have been observed in individuals with poor 
baseline neuropsychological performance or worse levels of immunosuppression. A 
recent prospective treatment effect study reported that regimens containing a higher 
CPE rank score were effective in suppressing CSF viral loads but were associated 
with worse neurocognitive performance [35]. Long term studies which examine both 
the neurocognitive profile and the CPE rank, as well as potential measures of anti-
retroviral neurotoxicity, will be needed to resolve these issues. 
The question of whether viral subtype or clade is responsible for differences in HAND 
has not been studied well enough in clinical populations. For instance, the 
neurovirulence of HIV clade C has been associated with less severe forms of 
neurocognitive impairment in some studies, but with equally deleterious effects in 
others [36-38]. Variability has been attributed to differences in the dicysteine motif 
within the neurotoxic region of B-Tat, producing a greater (or lesser) degree of Tat-
induced apoptosis [39,40]. However, other viral proteins such as gp120 may be as 
neurotoxic. The clade sequence, levels of proviral DNA and tat protein, together with 
their impact on neuropsychological functions and neuro-imaging findings, is the 
subject of a study currently being conducted by our group. These clade and viral 
neurotoxicity studies are needed to better understand mechanisms of HAND. 
However, where these studies are conducted across different regions with differing 
culture and language effects on neuropsychological test performance, the need for 
standard approaches to clinical characterisation of HAND becomes more pressing. A 
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possible clade-specific difference has already emerged in our preliminary work, 
wherein we found that HIV positive participants performed as well as HIV negative 
controls on the grooved pegboard test, a measure consistently used to ascertain 
whether HIV associated subcortical neuropathology exists [41,42] 
Given that prospective treatment effect studies afford many advantages to better 
understand the impact of viral, treatment and other individual factors on HAART, this 
systematic review will undertake to examine all such published studies. In particular, 
the methods of classifying of HAND will be discussed with a view to describing an 




The search for studies was conducted using four approaches: 
1) Using a key word search of the following databases conducted on 12 March 
2009: 
i) a. PUBMED: HIV [mh] OR Acquired Immunodeficiency Syndrome [mh] 
OR AIDS [tw] OR HIV [tw]) AND (Anti-retroviral Therapy, Highly Active 
[mh] OR HAART [tw]) AND (Cogniti* Disorders [mh] OR memory [mh] OR 
memor* [tw] OR cognition [mh] OR cogniti* [tw] OR AIDS Dementia 
Complex [mh] OR Neuropsychological Tests [mh]). All clinical types of 
studies on adults were included.  
ii) PsycINFO: AIDS and HAART and NEURO.* 
 
2) Reviewing the reference sections of articles found in this way and searching for 
relevant publications. 
 
3) Using a hand search to review the tables of contents of key journals, searching 
for relevant publications. These key journals included: AIDS, AIDS and 
Behaviour, AIDS Care and STDs, Archives of Neurology and Neurology. 
 
4) Personal communication with key researchers in the field. This was defined as 




The search strategy and retrieved articles are shown in figure 1. 
 
Inclusion and exclusion criteria 
We included peer-reviewed published studies in which a clinical sample received a 
neuropsychological and neuromedical assessment before or during early treatment 
(defined as within one month of commencement) of HAART, and again within 24 
months. A minimum treatment period of two months was required. A clear 
categorisation of EITHER a neurocognitive disorder OR of global/overall 
neuropsychological status in patients needed to be reported at both time points. The 
included studies were defined as prospective treatment effect cohort studies. 
  
We excluded cross-sectional and prospective observational studies where 
comparisons were made between treatment-naïve and HAART-treated groups or 
where neuropsychological changes over time were assessed in participants already 
using HAART/ not HAART naïve. Our primary aim was to describe the pre-treatment 
factors which may predict or be associated with HAND outcomes. In addition, the 
dynamics of neuropsychological profile and neuropsychological change are known to 
be different in individuals who are not HAART naïve (for example, see Robertson, Su 
et al. (2007), wherein it is reported that treatment interruption resulted in improved 
neuropsychological function). We also excluded studies of children and studies 
where the neurocognitive status OR neuropsychological profile was not reported at 
the two time points. 
 
Study sorting 
All articles retrieved on electronic search were loaded into a single Reference 
Manager™ database (See figure 1). Duplicates were removed. This left 108 studies. 
Using the criteria set out above, the database was reviewed by two of the authors, 
independently and respectively (JJ and HG), to ascertain reliability of inclusion and 
exclusion. The kappa was 0.76. Where there was disagreement, the non-included 
study was discussed and a decision made as to its suitability. After this stage, 15 
studies were identified. The papers were reviewed to establish suitability in terms of 
two criteria: they needed to report neuropsychological or neurocognitive profile in the 
same sample at the two time points. Duplicate publications from the same dataset 
were omitted. Once the electronically retrieved articles had been sorted, these were 
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reviewed and data extracted using a spreadsheet with key fields. The reference 
sections of papers reviewed in this way were then screened for other potential 
studies. Additional studies were discussed between the two reviewers and data 
extracted. Finally, we wrote to all first authors requesting their willingness to review 
the reference list and to suggest any papers or studies that they felt needed to be 
included. A final list of 15 studies was reached. 
 
We also reviewed the quality of studies using a simple Likert-type scale of three 
areas: (1) assessment - did the study utilise a neuropsychological test battery 
including at least 3 domains of function, and was this repeated both before initiating 
and after a period of time on HAART; (2) reporting - did the study report on the full 
neuropsychological assessment both before and after HAART, and did it indicate 
whether the first assessment occurred prior to initiating HAART; and, (3) confounders 
- did the study report on the assessment of potential confounding factors such as 
neurological conditions, psychiatric disorders or substance misuse. Each domain was 
rated on a scale of 0 for no, 1 for partly, and 2 for yes. In this way, high quality 
studies could be viewed as scoring between 4 and 6, intermediate quality studies 
between 2 and 3, and lower quality studies less than 3. 
 
RESULTS  
Nature of studies 
The majority of studies identified were conducted in the USA, where clade B is 
predominant (n=11); the remainder consists of one each completed in Brazil and 
Thailand, and two in Uganda (Table 1) [43-46]. Where reported, almost all studies 
were done in infectious diseases clinics or in research projects that were associated 
with such clinics. Sample sizes of HIV positive individuals included in these studies 
range from 14 to 126, with one large study including 303 individuals. The mean 
sample size was 69, with a median of 49. Most studies report good follow-up rates, 
with only two studies managing to review less than 80% of recruited subjects (67.7% 
and 71.4% respectively). The mean age of participants was 37.05 years, and ranges 
from 29.7 to 45.2 years. Studies report a wide range of gender distribution, while the 
mean percentage of men included was 66%. Seven studies reported on 
ethnicity/racial distribution of participants. For the majority that did, either “non-white” 
or “African American” groups were listed. The percentages of these “non-white” 
participants ranged from 18-78%. In most cases, the degree of immuno-suppression 
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at study entry was significant, with a mean CD4 cell count in all included studies of 
179.2 (53-392.2). This mean improved to 285.8 after HAART use (148.5-337. Note 
that the post-HAART CD4 count for the study reporting a higher CD4 count at study 
entry was not provided). Similarly, the pre-HAART mean viral load in log10 copies 
was 4.64 and improved to 3.29 post-HAART.  
 
Measures 
The clinical assessment of neurocognitive disorders requires the exclusion of 
confounding causes (see table 2). Most studies (n=10) utilise either a psychiatric 
history or make use of rating scales to exclude participants who suffer from 
psychiatric disorders. Of those that use rating scales, two use the Centres for 
Epidemiology rating scale for Depression (CES-D), and one each use the Hamilton 
Depression Rating Scale and Thai Depression Inventory. Patients with current 
psychiatric disorders are generally not included in studies of HAND. Similarly, four of 
the 13 studies do not formally report on the screening of substance use disorders. 
Those that do, use a combination of self-report and clinician-interview, with only two 
using formal drug testing procedures. Only two studies formally report on the 
exclusion of concomitant neurological problems. Most utilise some type of 
standardised clinical or neurologic examination. Only one study, which aimed to 
correlate the use of HAART with magnetic resonance spectroscopy findings, utilised 
formal neuro-imaging to exclude intra-cranial pathology [47]. Regarding the reporting 
of functional assessment, only four studies note this, with three reporting impairment 
of function using the Karnofsky score. In these, the scores range from 66 to 84. 
 
The prevalence of neurocognitive disorder is noted in nine studies, with three utilising 
the Memorial Sloan Kettering (MSK) score. Many of the studies recruited participants 
from specialised clinics, and in most cases, sought to include people with established 
HAND. The prevalence of people who had normal MSK ratings ranges from 4% to 
69%, while 21% to 48% had “equivocal” ratings, 10% to 61% had stage 1 scores and 
one study reports a prevalence of 7% of stage 2 scores. Three other studies report a 
prevalence of HAD ranging from 22.4% to 61% [9,48].  
 
Neuropsychological test batteries 
In the studies included in this review the neuropsychological test batteries vary 
widely. In general terms, half of the studies include formal tests of verbal learning, 
with three using the California Auditory Verbal Learning Test, three the Rey Auditory 
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Verbal Learning Test, and one an unspecified verbal learning test. Psychomotor 
speed is tested using the Trail-Making Test B (TMT B) in seven instances, and the 
Color Trails 2 in two instances. In addition, the Grooved Pegboard (either dominant 
hand or non-dominant, or both) is used in eight of the batteries. Executive functions 
are assessed using a variety of tests, including the Stroop Color-Word Test (n=4), 
and components of the trail-making tests (TMT B or Color Trails 2). The Digit Symbol 
Substitution Test, a test of attention and speed of processing, is used in ten batteries. 
 
Use of HAART 
A wide range of HAART regimens are reported and there was no emergent trend. 
Studies where these are specified note regimens based on non-nucleotide reverse 
transcriptase inhibitors (NNRTI’s) (efavirenz in 2 cases, nevirapine in 2 cases), while 
in others protease inhibitor-based regimens are reported (n=3). The duration of use 
ranges from eight weeks to two years, but most (n=8) utilise an average study period 
of six months. In studies reporting non-significant neuropsychological improvement, 
the HAART regimen is noted in two of three cases: in the one study a combination of 
AZT, 3TC and EFV was used, while in the other an unspecified combination of 
NNRTI’s was used. These regimens both rank CPE >2.  
 
Neuropsychological outcomes 
Studies included in this review report on neuropsychological outcomes in a number 
of different ways (see table 2). In some instances, neuropsychological data are 
compared to an HIV-negative group. Most of the included studies (n=11) note a 
significant improvement in neuropsychological function of individuals following 
HAART initiation. In most instances, investigators make use of z-scores based on 
population norms (seven of the eleven studies), with most using a composite z-score 
based on combinations of neuropsychological tests (NPZ). It was not possible to 
generate a pooled effect due to the variability in the number of tests used for 
calculating the NPZ scores in different studies (for example, NPZ4 or NPZ6). In two 
studies where composite z-scores pre-and post-HAART are reported, the scores 
improved from -0.74 to -0.52 [49] and -0.62 to 0.29 [50] respectively. There were 
three studies that do not find significant improvements in neuropsychological function 
following initiation of HAART. In one, the authors report that this may be explained by 
the fact that HAART may improve more severe HAND (such as HAD), as opposed to 
milder forms, and that their sample size was small (14 participants) [51]. In another 
study, the specific focus was on hepatitis C co-infection, and while there was a trend 
to improvement on HAART, it does not reach significance [52]. The remaining study 
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reports separately on HAART responders and non-responders; there were more non-
responders than responders (39 vs 19). No reason for this disparity is provided [9]. 
 
Quality of studies 
When we conducted a review of the quality of the studies, using the method 
described above, we found that most are high quality studies (n=8), with only one 
study rating less highly (should this be referenced?). This particular study was 
published as a brief report, and could have excluded certain clinical parameters for 
the sake of brevity. What is striking is that most studies do not report on or address 
all of those factors which may be considered as comprising a detailed and high 
quality study of HAND. For example, four studies do not report on any assessment of 
substance misuse and only two note any neuro-imaging findings. In addition, only 
four studies formally report on functional assessment. It may be suggested that more 
formal reporting of these issues are needed to fully appreciate the complexity of the 
diagnostic issues in HAND.  
 
DISCUSSION 
To our knowledge this is the first systematic review examining the effect of initiating 
HAART in a prospective treatment effect cohort of people with HIV. Our findings 
support the existing literature that, in general, the initiation of HAART results in 
improvement of neuropsychological function. Although the duration of treatment most 
often reported was only six months, improvement was neither full nor universal. 
Factors contributing to the variety of treatment responses include genetic 
vulnerabilities, co-morbid substance abuse, viral resistance and neurovirulence 
factors, and host immune and inflammatory responses. These have only been 
explored to a limited extent in these prospective cohort studies. In addition, these 
studies vary greatly in their methodologies, leading to difficulties in interpreting and 
collating these findings.  
 
In this review, a significant improvement in either neurocognitive status or 
neuropsychological profile was reported in eleven of the 15 studies. It was not 
possible, due to the variability of reporting, to conduct formal meta-analysis, although 
this would clearly be desirable. In most instances these improvements were noted 
across a number of different neuropsychological domains. It may be possible in 
subsequent reviews or meta-analyses to identify whether particular domains improve 
more than others and over what period of time. Deficits reflective of a loss of cortical 
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neurons, for example, may be more persistent than ones suggesting white matter 
damage, which may be reversible. Such studies may best employ specific neuro-
imaging techniques coupled to neurocognitive assessment. In studies that did not 
find significant improvement in neuropsychological function, it is suggested that the 
nature of HAND studied may have been a factor. In particular, it is now known that 
while HAD occurs less commonly in the HAART era, milder forms are becoming 
more frequent [5]. In this way, it is possible that HAART has a greater mitigating 
effect on severe HAND, and less so on milder neurocognitive disorders. 
 
We also note that different investigators report on this field very differently. In the first 
instance, there is little uniformity in the selection of neuropsychological tests. Whilst 
there is general agreement about the nature of HIV-related neurocognitive 
impairment, test batteries vary both in length and structure. It could be argued that a 
greater uniformity would lead to improved comparability across not only different 
regions (and viral clades), but also between different study questions (for example, 
some studies examine co-infections while others examine CSF viral loads). In this 
regard, investigators across studies may consider using an agreed upon minimum 
number of tests- for example six tests measuring three domains which must include 
memory, psychomotor and executive functions. Specific tests may also be agreed 
upon, particularly where language and cultural effects may be regarded as less 
influential. Examples include the grooved pegboard test, the digit symbol test, and 
the color trails test. The adoption of such an approach does not, however, remove 
the need for age and language appropriate norms. In addition to test batteries, few 
studies include a description or classification of HAND. While it is understandable 
that the key to understanding the mechanism of neuropsychological change requires 
that such scores are reported in detail, the provision of diagnostic categories and 
prevalence would again aid in the understanding of regional differences in severity 
and course. Other challenges identified in this review are that sample sizes were 
mostly small, with most studies including less than 100 participants, although follow-
up rates are generally very high. These cohorts do allow for intra-individual 
comparison, but they are limited in their ability to report on categories of HAND and 
the associated factors or predictors of severe types of cognitive disorder.  
 
A key issue that has emerged in the understanding of neurocognitive change or 
improvement over time is the duration of treatment and the point at which follow-up 
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assessment is made. A recent study has highlighted the variability of this 
improvement, noting that in some individuals improvement occurs within the first 
weeks of HAART, while for the majority of individuals this may occur after up to a 
year [53]. These findings seem to contribute to the notion of the variable course of 
HIV-D, as noted by Nath and others [5,6]. The “early improvement” group might be 
associated with a greater degree of baseline impairment, and with clinical and 
immunological features suggestive of an inflammatory process, as well as with good 
viral suppression on HAART [54]. Discriminating between those with active disease 
and those with “burnt out” or stable deficits may not only provide indicators as to 
factors driving disease activity, but may also be relevant to developing targeted or 
adjuvant treatments. Given that the majority of people living with HIV/AIDS (PLWHA) 
continue to improve from six months, the importance of following these individuals up 
to one year and probably beyond is critical to understanding further the effects of 
HAART in the long term. 
 
Research into the predictors of response to HAART is essential to informing the 
clinical practice likely to produce the best outcomes. The measurement of peripheral 
blood CD4 count and viral load is considered standard practice before and during 
HAART. In addition to a low baseline CD4 nadir being predictive of HIV-D, the 
suppression of peripheral viral load has consistently been linked to better 
neurocognitive outcomes in the face of good adherence to HAART [55]. The role of 
CSF analysis is less clear, with good CNS penetrating HAART being associated with 
suppression of CSF viral load and good neurocognitive outcomes in some studies, 
but with either failure to suppress or adverse neuropsychological performance in 
others [10,56,57]. In this review, of the studies reporting neurocognitive improvement 
on HAART, only three reported on baseline and follow-up peripheral viral loads. In all 
three there was significant improvement in this parameter, and in all cases 
suppression of peripheral viral load was directly associated with suppression of CSF 
viral load. Corresponding measures of CNS inflammation were examined only in one 
study using MRS [47]. In one other study, peripheral monocyte HIV DNA was 
associated with poorer neuropsychological performance at 48 weeks, suggesting that 
the peripheral pool of infected monocytes may stimulate ongoing CNS inflammation 
[58]. Further cohort studies wherein other measures of immune and inflammatory 
response (such as cytokines), inflammatory protein (for example amyloid) and 
imaging markers (such as diffusion tensor imaging) are addressed, should be 
conducted. Other baseline characteristics, such as anti-retroviral drug resistance, 
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may predict neurocognitive outcome. In a recent study it was reported that the 
presence of anti-retroviral resistance mutations may be associated with diminished 
neurovirulence [59].  
 
The importance of obtaining locally derived population normative data is central to 
the neuropsychological characterisation of impairment. In general the approach has 
been to generate these data from either matched or similar groups of individuals 
within the population under study. The degree to which these groups are regarded as 
similar is often based on the cultural and language expression of the group in 
question, and it is these parameters which drives the development of new normative 
datasets [60]. While other demographic factors such as education are well known to 
exert significant effects on test performance, there may be other difficult-to-measure 
group variables which also do so and which may result in the over-diagnosis of 
HAND [4]. So, while good normative data represent an essential starting point for 
conducting research into HAND, the deconstruction of cultural and linguistic variables 
may be needed to make a test battery truly relevant to the group under study [61].  
 
Much of the literature examining neurocognitive disorders could not be included in 
this review, mainly due to the absence of cohort-type studies. In many instances, 
studies comparing HAART-naïve and HAART-using groups were made, but not in 
the same individuals. Many studies we initially found were excluded because they did 
not make use of formal neuropsychological measures. This has been emphasised by 
many as the key to the diagnosis of HAND [62]. This analysis was limited by the 
small number of included studies, but we believe that our findings remain important 
and valid. In particular, the variability among studies and their differing approaches 
was evident.  
 
There is clearly then a need for further studies examining the effect of HAART in a 
cohort of well-characterised individuals, and preferably making use of tools that allow 
for comparison with other studies. Given the constraints of resource-limited settings 
in terms of time and skills, we would recommend that a neuropsychological battery 
for use in international settings might include tests of the following domains: attention 
and concentration, verbal memory, psychomotor function and executive function. 
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Tests selected for use require age and educational appropriate norms, and should be 
properly translated into the local language. A longer battery has been used 
successfully in cross-cultural settings (see [63] and [64]. In addition, we recommend 
the use of a brief activities of daily living scale - we have adapted the Lawton Brody 
Scale for this purpose [65]. An assessment of neurologic status is a pre-requisite, 
and should be structured to examine neurological functions affected in HIV/AIDS. 
Structured or semi-structured clinical interviews are needed to establish substance 
use history and psychiatric disorder status. Together, this approach will allow at least 
for some standardisation across studies and regions. In order to address the issue of 
treatment effect, it is suggested that studies clearly report on HAART regimen used, 
duration, and possibly CPE rank. The reporting of neuropsychological test means 
and standard deviations would allow for potential meta-analytic approaches. 
 
In the next chapter , the baseline neurocognitive characteristics of individuals 
commencing HAART are described, using an international neuropsychological 
battery outlined above- and adapted for use in South Africa. The assessment 
included functional and neurologic assessment. This would be the first study in South 
Africa using a detailed battery to assess neurocognitive function across a number of 
domains. In addition, the next chapter reports on whether a number of demographic 
and clinical variables are associated with HIV-associated dementia (HAD)- the most 
severe form of HAND. The inclusion of apolipoprotein E (APOE) genotyping at this 
assessment (as reported in chapter 5), adds to knowledge regarding the putative role 
of APOE as a vulnerability factor for HAD. In chapter 7, I present data from the re-
evaluation of neuropsychological function at one-year using the same detailed 
battery, in order to address the question raised by this review- whether the use of 
HAART is associated with neurocognitive improvement in individuals infected with 
clade C HIV; and whether there are associated or predictor variables of this change. 
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Figure 1: Results of search 
strategy
All abstracts reviewed by JJ and HG for inclusion and 
exclusion: 13 studies included 
 
Full papers of included abstracts reviewed for inclusion: 8 
studies included (5 of the previous studies excluded) 
Study data extracted and reference sections reviewed: 
Inclusion review by both JJ and HG 
Further 2 studies included and data extracted 
 
Experts consulted on reference list and hand search of relevant 
journals 
5 studies added. 
 
Completed extraction and analysis: 15 studies 
Electronic search: Pubmed (n=83), PsycInfo (n=30) 
Total 113 studies retrieved, 108 unique 
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Table 1. Descriptive variables of studies examining neurocognitive function before and after initiating HAART 



















USA Research clinic 
59 HIV+ and 
55 HIV- 
91.2 29.7 14.2 100 392.2 
Not 
reported 






14 71.4 35.5 8.4 57 134.6 239.1 4.56 <80 to 25 000 
Chang 1999 USA 
Infectious diseases 
centres 
16 HIV+ and 
15 HIV- 
100 44.3 Not reported 88 163 274 Not reported Not reported 
Clifford 2005 USA 
Infectious diseases 
centres 
303 93.4 37 Not reported 81 219 
Not 
reported 
4.74 Not reported 






100 33.2 12.2 0 64.9 119.4 77978 48226 
Cysique 
2009 




50% LDL at 
week 12 
Marra 2003 USA Not specified 
Total 25- 13 
HAART naïve 
88 34.5 13 92.9 207 
Not 
reported 
4.73 Not reported 
Marra 2009 USA Research clinic 79 (44 naïve) 60 39 13 83.5 111 
Not 
reported 
4.86 Not reported 
Parsons 
2006 










MACS cohort infectious 
diseases clinic 




by 60  
Not reported 







MACS cohort infectious 
diseases clinic 
49 100 45.2 
% college: 57-
70 







Clinic, Mulago Hospital 









HIV+ 9.1 (4.3); 
HIV- 10.3 (4.2) 





neurology clinics, HIV 
testing centres 





Table 2. Clinical and neuropsychological characteristics  











Test Battery NP Baseline NP outcome  
Baldewicz 
2004 















but not specified; 
duration not 
specified 
FT, Ruff 2 and 7 Selective 
Attention Test, CVLT, TMT B, 
SCWT, DSS-W-R 
All domains reported as 
F-scores and significantly 
different from HIV- 
controls 
Average z-score by 
domain over time: 
AIDS fine motor 0.2, 
attention 0.4, memory 
0.55, executive 0.4, 











AZT, 3TC, EFV; 




Memory, Visual Recognition 
Test, Word Span, SCWT 


























9.1 (3-14) months 
HDS plus neuropsychological 
evaluation not reported, 
providing Karnofosky and ADC 
staging 
HDS 10.3 HDS 12.2 
Clifford 
2005* 
On history, IDU 1 










EFV and non-EFV 
groups; duration 
24 weeks 
TMT A/B, DSC-W-III, NPZ3   
-0.09 (EFV) and -0.03 
(non-EFV) Z-score 
0.51 and 0.61 




interview for alcohol: 
46% alc, 20.6% IDU 
and 38.9% illicit subs 
within last 6 months 














GP D, CTM 1/2, COWAT, FWL 
 HAART SD: CT1 49.8 
(19.9), CT2 106.5 (31.8), 
COWAT 24.2 (8.4), GP D 
87.0 (36.5), FWL 3.1 
(1.1) 
HAART SD (change): 
CT1 41.3 (11.0-sig), 
CT2 89.6 (19.0-sig), 
COWAT 22.5 (-1.0), 
GP D 81.0 (8.6-sig), 




















CPE rank mean 
1.4, duration 48 
weeks 
GP D and ND, PASAT, TMT A 
and B, Letter Fluency (F,A,S) 
GDS 1.44 (0.93) 
13.5% improvement at 
12 weeks, 40.9% at 
36 weeks, and 33.3% 













Indinivir, AZT and 
others; duration 8 
weeks 




NPZ4= -0.31 (-0.83-1.01) 
NPZ not specifically 
reported, but 
improved significantly 











at 39% of visits, 
duration 52 weeks 
NPZ4: timed gait,  GP 
dominant, digit symbol, FT 
non-dominant; NPZ8: add 
RAVLT, GP non-dominant, 
TMT A and B, FT dominant, 
CalCAP 
NPZ4=-0.29 (-0.96-0.14); 
NPZ8= -0.24 (-0.70-0.15) 
NPZ4 in those on 3 
ARVs was 0.36 (s); 





abuse- alcohol 16 
drinks per month, 
cocaine 0.85 days 
per month, cannabis 













duration 6 months 
Ruff 2 and 7 SAT, PASAT, 
Computerised  Reaction Time 
Tasks, DS
1










z-score -0.78 z-score -0.55 (ns) 
Robertson 
2004* 















10% stage 1 
Not specified; 
duration 6 months 
Ruff 2 and 7 SAT, PASAT, 
Computerised  Reaction Time 
Tasks, DS
1
, TMT A/B, SCWA, 
COWAT, RAVLT, ROCF, GP
2
, 
FT, TG, Vocabulary -WAIS-R 
Total z-score -0.74 Total z-score -0.52 
Sacktor 
2000* 






HAD 61% at 
baseline 
Various including 
PI; duration 2 
years 
GP D/ND 
23/30 had GP ND z-
score <-1.0 




Screened on history 
















DSMT and TMT B 
Symbol digit -1.45; TMT 
B -0.825 
Symbol digit --1.025; 
TMT B -0.225 
Sacktor 
2006* 



















(n=5); duration 6 
months 
WHO-UCLA AVLT, GP 
D/ND,DSMT, Timed Gait,  CT 
1/2,  DS F/B, Karnofsky 
Performance Scale, MSK   
z-scores: WHO-UCLA 
AVLT total -1.7, GP D -
0.4, GP ND -0.2, CT1 -
1.2, CT2 -1.5, DSF -0.7, 
DSB -0.7 
z-scores: AVLT -0.1, 
GP D 0.2, GP ND 0.3, 
CT1 -0.1, CT2 -0.3, 





















33% stage 1, 





duration 6 months 
WHO-UCLA AVLT, Timed 
Gait, Finger Tapping, GP 




Karnofsky Performance Scale, 
MSK  
z scores: AVLT total -1.2, 
CT1  -1.7, CT2 -2.8 
SDMT -0.8, GP D 0, GP 
ND -0.7, FT -1.0, TG 2.7, 
Verbal Fluency -0.4  
z scores: AVLT total -
0.1, CT1  -0.4, CT2 -
1.3 SDMT -0.3, GP D 
0.4, GP ND 0.3, FT -
0.5, TG -1.8, Verbal 
Fluency 0  
Valcour 
2009* 















IHDS, RAVLT, timed gait, 
DSMT, NPZ 
IHDS 10.2; NPZ 
composite score -0.62 
NPZ comp 0.29 
 
*denotes studies in which there was significant improvement in NP outcome after initiating HAART 
Key to abbreviations used for neuropsychological tests: 
ADC = AIDS Dementia Complex; AVLT = Auditory Verbal Learning Test; COWAT = Controlled Oral Word Association Test; CTM 1/2  = Colour Trails 1 and 2; CVLT = California Verbal Learning Test; DSMT = Digit Symbol 
Modalities Test; DSS-W-R = Digit Symbol Subtest WAIS-R; DSC-W-III = Digit Symbol-Coding Subtest – WAIS III; DS = Digit Symbol; DSS-WR = Digit Symbol Subtest – WAIS R; DS F/B = Digit Span Forwards and Backwards;  
FT= Finger Tapping; FWL = Four Word Learning; GP D/ND = Grooved Pegboard dominant hand/ non-dominant hand; HDS = HIV Dementia Scale; IHDA = International HIV Dementia scale; Complex Figure Test
 
–IM and DR = 
Complex Figure Test – Immediate memory and delayed recall; MSK = Memorial Sloan Kettering Dementia Stage; NPZ = Neuropsychological Z-score (composite); RAVLT = Rey Auditory-Verbal Learning Test; ROCF = Rey-
Osterrieth Complex Figure, SAT= Selective Attention Test; SCWT = Stroop Color-Word Test; SW = Stroop Word; TMT A/ B = Trail Making Test A/B;  TG= Timed gait; WHO-UCLA AVLT = World Health Organization-University 
of California-Los Angeles Auditory Verbal Learning Test 
1
 Indicates test not specified 
2
 Indicates dominance not specified 
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HIV- Associated Neurocognitive Disorders (HAND) exert an impact on everyday 
functions, including adherence. The prevalence of and risk factors for HAND in 
patients commencing anti-retroviral therapy in Southern Africa are unknown.  
Participants from primary care clinics in Cape Town, South Africa underwent detailed 
neuropsychological, neuropsychiatric and neuromedical evaluation. Using the 
updated American Academy of Neurology criteria, participants were classified into 
categories of HAND, and demographic and clinical risk factors for HIV-dementia 
(HIV-D) were assessed. The prevalence of mild neurocognitive disorder (MND) and 
HIV-D were 42.4% and 25.4% respectively. There were significant associations 
between lower levels of education and older age with HIV-D, and a trend to 
association with HIV-D and lower CD4 count.  In a regression model, a lower level of 
education and male gender were predictive of HIV-D. These findings suggest that 
HAND are highly prevalent in primary care settings in South Africa where clade C 
HIV is predominant.  
 




Data on HIV-associated neurocognitive disorders come mainly from high-income 
countries. While some data exist for Uganda, there have been none conducted in 
South Africa using the detailed approach outlined previously. This standard approach 
is necessary for comparison across regions and to formally document the impact that 
clade C HIV might have on neurocognitive function. In addition, there are other 
important regional differences, which could be ascribed to social and demographic 
factors- namely, that our HIV epidemic is marked by a majority of women; that 
individuals enter care late (and by inference may have higher levels of immune-
compromise and greater levels of neurocognitive impairment); and that resources for 
assessment and treatment are few. In this chapter, I document these factors and 
report on the extent to which they may be associated with HIV-associated 
neurocognitive disorders or specifically, HIV-associated dementia (HAD). I included 
the International HIV Dementia Scale in this baseline assessment and compared it to 
our research diagnostic categories, in order to establish its utility- these findings are 
reported in chapter 6. 
HIV associated neurocognitive disorders (HAND) remain prevalent in the era of 
HAART. Rates of HAND of up to 50% have been reported [1].  Such disorders impact 
negatively on social and occupational functioning. In addition, they may be 
associated with increased risk behaviors and decreased adherence to medication [1-
3].  Although the prevalence of HAND is well-established in some regions, there is 
less data on prevalence and risk factors in areas where clade C HIV predominates, 
such as South Africa, 
The diagnosis of HAND rests on neuropsychological, as well as psychiatric and 
medical evaluation [4].  In busy primary care settings, clinicians usually do not have 
access to detailed neuropsychology, and therefore need to make use of clinical 
assessment or brief screening tools [5]. A number of diagnostic research approaches 
have been proposed, including  the updated criteria of the American Academy of 
Neurology (AAN), and the Memorial Sloan Kettering staging (MSK) of HIV Dementia 
(HIV-D) [6,7]. The AAN system proposes four categories: “normal”, “asymptomatic 
neurocognitive impairment (ANI)”, “mild neurocognitive disorder (MND) and “HIV-
dementia (HIV-D)”. The ANI, MND and HIV-D categories are used when an 
individual’s performance on a range of neuropsychological tests falls below age and 
education-defined norms in at least two domains of function. In the absence of 
everyday functional impairment, the ANI category is used, while the MND and HIV-D 
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categories are used when everyday impairment is mild to moderate or severe, 
respectively.   
Given that HAND are both common and exert deleterious effects on everyday 
function including adherence to medication, it is important to identify and address 
potential risk factors. To date, several risk factors for HIV-D have been established, 
including lower CD4 count [8], advancing age [9], lower levels of education [10], and 
drug and alcohol abuse [11]. Depression has also commonly been reported to both 
co-exist with HAND as well be associated with severity [12,13]. In South Africa, high 
rates of alcohol and substance abuse have been reported in HIV clinic attendees 
[14]. The role of nutritional factors such as vitamin B12 and folic acid in the 
development of cognitive impairment is well known, but less clear in HAND.   They 
may have particular relevance in regions where poverty and malnutrition are 
common.  Other factors such as HIV subtype (clade) are now thought to be 
significant [8,15]. While clade B has been proposed to be more neurotoxic, clinical 
studies in India, and a study utilizing a brief cognitive screen in South Africa, 
suggested that individuals infected with clade C may be at equal risk of developing 
HAND [16,17].  
We undertook a detailed evaluation of neurocognitive disorder status and possible 




All participants who met study criteria and agreed to participate provided written 
informed consent. Approval to conduct the study was obtained from the research 
ethics committee of the Faculty of Health Sciences, University of Cape Town, and 
from the relevant health authorities.  
 
A total of 283 HIV-infected individuals were invited to participate at three primary 
health care centres in Cape Town, South Africa from February 2008 through August 
2009. All potential participants were ambulant and able to attend out-patient visits. A 
study nurse screened clinic attendees randomly drawn from the day’s list on 
assigned days. To be included, participants were (1)  HAART naïve and in a pre-
treatment phase of counseling, (2) aged 18-35 years, (3) had a positive diagnosis of 
HIV infection made within the last six months (includes initial and confirmatory tests) 
and (4) at least seven years of formal education. In order to diagnose HAND, it is 
necessary to exclude other potential causes of neurocognitive problems. We elected 
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to restrict participants to a younger age in order to reduce the impact of age-related 
illness, and the education criteria to reduce the potential effect of poor education and 
intellectual disability. We also excluded participants if they had a history of severe 
mental illness, such as schizophrenia and bipolar disorder (assessed using the Mini 
International Neuropsychiatric Interview- MINI [18]). We also excluded those with 
active major depression (assessed with the Centers for Epidemiological Study- 
Depression scale [19]), a recent (6 month) substance abuse history (assessed with 
the Alcohol Use Disorders Identification Test-AUDIT [20]- and a history of head injury 
with loss of consciousness exceeding 30 minutes. Participants completed a series of 
assessments after screening, and were then given appointments to attend a second 
study visit at Groote Schuur Hospital. HIV negative control participants (n=51) were 
recruited by invitation from Voluntary Counseling and Testing services at the same 
community clinics. Other than being HIV negative, as confirmed by a recent rapid 
HIV test and confirmatory serological test, inclusion and exclusion criteria were 
identical in the HIV positive and the control groups. Of the originally screened 283 
participants, 170 completed the full assessment. Reasons for not attending the 
second assessment included financial constraints, could not get away from work, and 
travel out of Cape Town. We felt that this group was reflective of the clinic sample in 
question because we noted that the above logistical problems in tracking participants 
into the second visit most likely accounted for this rate of completion (that is, factors 
independent of participant variables). In addition, participants not attending due to 
possible neurocognitive factors would lead to an under-estimation of the prevalence. 
 
The lowest pre-treatment CD4 cell count was obtained from the clinic records. This 
was assumed to be the nadir count, as all participants were entering treatment. 
Clade sequencing was not available on this sample at this time but 89% of infected 
individuals in Cape Town area are infected with clade C virus [21]. Hepatitis sero-
status was not established but the prevalence of hepatitis C in South Africa is 
extremely low [22].  
Procedures 
Once they had signed informed consent, participants completed a series of 
psychiatric and demographic questionnaires, which included measures of depression 
and substance abuse status (as above), as well as reported function and quality of 
life scales (the Patient’s Assessment of Own Functioning- PAOFI- and the Quality of 
Life and Satisfaction Scale- QLESQ). All instruments were forward and back-
translated into the first language of the participants.  
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Neuropsychological test battery 
A neuropsychological test battery was administered to all participants to assess 
specific domains neurocognitive function. Our rationale for selecting the particular 
battery was first, that the battery represented measures of domains typically affected 
by HIV [23]; second, the battery made used of tests commonly used in international 
settings so as to be able to make  findings comparable; and thirdly, the battery 
needed to be adapted to be locally suitable. We  based the battery on that used by 
the HIV Neurobehavioural Research Center (located at the University of California, 
San Diego) [24]. We sought advice on translation and applicability from three local 
expert neuropsychologists. Changes to word lists to reflect local language and idiom 
were made. All instruments had their instructions and content translated into isiXhosa 
and Afrikaans- instructions were also back-translated for fidelity. The battery 
comprised tests of the following domains: Attention (the Mental Alternation Test and 
the Mental Control Test), learning and memory (the Hopkins Verbal Learning Test 
and the Brief Visuospatial Memory Test), motor (Finger tapping  and Grooved 
Pegboard- both dominant and non-dominant hands), psychomotor speed (Trail-
Making part A, Color Trails 1 and Digit Symbol coding) executive function (Colour 
Trails 2, the Stroop Colour Word test, the Wisconsin Card-Sorting Test and the Rey 
Complex Figure), and language (Category fluency animals and  Category fluency 
fruit and vegetables).  
 
Data from the 51 HIV negative controls were used to generate Z-scores for 
establishing the degree of impairment. No published norms are currently available in 
South Africa, and as most participants spoke isiXhosa, we elected to generate 
control data from similar community participants.  
 
Determination of neurocognitive disorder status 
We used the above neuropsychological test battery, together with scores from a 
neuromedical assessment and an evaluation of functional assessment to classify 
participants into one of four HAND categories, based on the updated American 
Academy of Neurology criteria [25]: no impairment, ANI, MND and HIV-D. We used 
z-score cut-offs of >2 SD and 1-2 SD in order to classify participants into categories 
of neuropsychological impairment.  
 
In order to establish the presence and extent of functional impairment, we reviewed 
data from the PAOFI and QLESQ, as well as neurologic examination. The advantage 
of including a neurologic assessment is that it allows for a more objective measure of 
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impairment status. The neurologic examination included measures of peripheral 
neuropathy using both a visual analogue scale and assessment of vibration sense, 
ratings of motor tone and power changes, involuntary movements, primitive reflexes 
and the timed gait test. The presence of neurological findings was recorded using a 
standardized assessment, based on a previously defined tool [26]. Findings were 
then used to generate a neurologic raw score using a semi-quantitative scale. A final 
rank of 0, 1 or 2 was then assigned depending on the range of score on this scale. 
Functional impairment was recorded using the PAOFI as above. Similarly, ratings on 
these scales were used to generate a rank score of 0, 1, or 2. When assigning a 
HAND category, we reviewed scores for both methods of assessing functional 
impairment. From the neurologic scale, the presence of peripheral neuropathy was 
included as a potential correlate of HIV-D. We included this due to consistent reports 
of neuropathy co-occurring with HAND [27]. This was coded as either present or 
absent. The final classification was conducted by a consensus panel comprising two 
HIV neuropsychiatrists (JJ, JH) and a neurologist (MC). 
 
Statistical analysis 
Analysis was conducted using STATA 10.0 (Stata Corporation, College Station, 
Texas, USA). Demographic, clinical and biochemical variables were compared 
across AAN-defined HAND categories using Fisher exact and Kruskal Wallis tests as 
appropriate. Variables which appeared to be associated with HAND categories in 
bivariate analysis were included in multiple logistic regression analysis comparing 
HIV-D to normal participants; variables were retained in the model if they 
demonstrated persistent independent association with HIV-D, or if their removal 




A total of 170 HIV+ participants were evaluated. The majority were women (n=126, 
74%), isiXhosa speaking (n=151, 89%) and had a median CD4 cell count of 168 
(IQR 115-199). The mean age was 29.5 years (SD = 3.65) and mean number of 
years schooling was 10.0 years (SD 1.85) (see table 1). Scores on the AUDIT and 
CES-D were low, ranging from 0-3 on both. More than half of patients had at least 
mild peripheral neuropathy (n=94). A range of other variables intended to establish 
the contribution of nutritional factors to neurocognitive impairment is presented in 
Table 2.  
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Utilising the AAN criteria, 43 of the 170 individuals (25%) evaluated met criteria for 
HIV-D, while 72 of 170 (42%) had mild neurocognitive disorder, and 15 of 170 (9%) 
met criteria for asymptomatic neuropsychological impairment; 40 individuals (24%) 
were assessed as being neurocognitively normal.  
 
In bivariate analysis, only age and level of education differed significantly between 
the groups (table 2). Patients with HIV-D tended to be older and less well educated. 
The CD4 cell count tended to be lower in those with HIV-D (p=0.051). Similarly, there 
were more men in the HIV-D category, although this did not achieve statistical 
significance across groups (P=0.055). There were no significant differences in any 
clinical or laboratory parameters associated with nutritional or systemic disease 
processes, including peripheral neuropathy. 
 
In a multiple logistic regression model comparing normal patients to those with AAN-
defined HIV-D status, level of education (p=0.001, odds ratio= 0.529) and male 
gender (p=0.048, odds ratio= 3.989) were predictive of HIV-D. In the model used, 
CD4 cell count was not associated with HIV-D status (p=0.718, odds ratio=0.999).  
 
DISCUSSION 
We report on the first detailed evaluation of HIV-associated neurocognitive disorders 
in patients attending primary care health facilities in South Africa where clade C HIV 
virus is prevalent. Using the updated American Academy of Neurology (AAN) criteria, 
we found a high prevalence of HAND. In particular, we noted rates of HIV-D of 25.3% 
and of MND of 42.4%. Furthermore, in this study population, level of education and 
older age were associated with AAN criteria for HIV-D in bivariate analysis, while 
both clinical and laboratory markers of nutritional and systemic disease process were 
not. The large number of individuals with MND has implications for possible 
progression to HIV-D, as does the related impairment in everyday function on various 
behavioural outcomes.  
 
The prevalence of HAND in this study is in keeping with other reports from the 
developing world. In Uganda 31% of individuals in ambulatory care met criteria for 
MSK-defined HIV-D, while in India 51% of individuals demonstrated significant 
neuropsychological impairment in at least two domains of function [26,28]. Studies in 
the developed world have reported similar rates of up to 27% [29]. In the study in 
India, the neuropsychological cut-off for impairment was 1.5 SD. This was lower than 
the standard cut-off employed in our analysis. While no other detailed research 
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approaches have been used in South Africa, there have been some reports using 
simple screening tools, wherein 24% of individuals demonstrated cognitive 
impairment using the HIV Dementia Scale [17].  
 
High rates of HAND may be explained by the fact that individuals in the public sector 
in South Africa access HAART very late, with a median CD4 count in our study of 
168 cells/ml. In this care system, access to HAART is provided to individuals with 
CD4 cell counts <200 cells/ml, or to those with a diagnosis of “HIV encephalopathy”, 
according to World Health Organization criteria. Accordingly individuals with CD4 cell 
counts >200 who have “HIV encephalopathy” would qualify for HAART, potentially 
reducing this burden of disease. Further work to improve screening for HAND in 
primary health care is needed. In addition to this primary prevention, whereby those 
with clinical disorder at higher CD4 counts could access HAART, there are 
implications for secondary prevention. In particular, individuals with HAND have 
some degree of impairment in everyday function, and so require substantial 
treatment support in order to improve adherence to medication [30].  
 
We found that level of education and age was associated with differences in HAND 
category, with participants with HIV-D being older and having a lower level of 
education. There was a trend to those with HIV-D having a lower CD4 cell count. In a 
parsimonious regression model, only lower level of education and male gender 
predicted HIV-D. While others have noted an association with CD4 count nadir and 
HIV-D [8], it is possible that the restricted range of CD4 count pre-HAART in this 
sample may limit this association. In addition, the small sample size may have limited 
power to detect associations. Both educational level and age are well known to affect 
neuropsychological performance [31]. In addition, the quality of education, insofar as 
it improves paper-and-pencil tasks, test attitudes and performance confidence may 
also affect test outcomes [32]. The effects of older age are now also known to be 
associated with an increased risk for neurocognitive disorder [9]. However, in this 
study, the differences in age and level of education between controls and participants 
were small and not likely to be clinically significant. We purposefully included only 
participants under the age of 45 to control for the effects of ageing. Study participants 
in this sample were generally drawn from a lower socio-economic group, and that this 
might be associated with poor nutritional status (reflected by anaemia or low albumin) 
that may contribute to the aetiology of HIV-D. In our study, this was not the case, and 
while haemoglobin values were in the low normal range, medians across AAN 
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categories did not differ. The impact of systemic disease, as measured by the proxy 
marker of low body mass index also was not significant.  
 
The category of MND also requires further study in prospective cohort studies. 
Firstly, there is growing evidence that HIV-D is a diverse clinical category, with a 
range of possible outcomes from improvement to deterioration [33]. Secondly, while 
the AAN categorical approach is useful to group individuals with similar types of 
neuropsychological impairment and problems with everyday function, it is likely that 
in reality, individuals with HAND fall on a clinical disease spectrum. Thirdly, while by 
definition, the MND category proposes that impairment of everyday function is mild to 
moderate, it remains a clinically measurable and significant outcome. In particular, 
these impairments have been linked to reduced rates of gaining and sustaining 
employment, impaired ability to manage finances and reduced driving ability [30]. 
The MND group in our study comprised 42.4% of the sample. Further research 
elucidating how this group changes over time is needed. This group may represent a 
precursor to HIV-D, in which case early treatment with HAART could be justified.  
 
Limitations of this study include the small control group size and the fact that 
normative data for isiXhosa speakers do not exist. However, efforts were made to 
recruit HIV-negative individuals from the same community and clinics as the HIV+ 
patients. While we attempted to remove potential confounding causes of 
neurocognitive disorder, we did not perform routine brain imaging or lumbar 
punctures on participants, due to resource and ethic constraints. We therefore could 
not ascertain with complete certainty that all neurocognitive disorder was due to HIV, 
despite careful clinical assessment.  In addition, we noted that of the 283 participants 
recruited at site, 170 attended the full assessment visit. This could have introduced a 
selection type bias. We felt that early logistic problems, such as financial constraints 
and accessibility- which were late addressed- most likely accounted for this drop-out. 
In addition, we noted that if participant factors such as neurocognitive disorder were 
at issue, then our findings would under-report the prevalence of these disorders. 
 
In summary, this study found that a high frequency of HAND exists in a region where 
clade C HIV is predominant. Nearly two-thirds of patients attending a primary health 
clinic were suffering from either MND or HIV-D according to rigorous AAN criteria. 
Correlates of HIV-D included lower education level and male gender. Further 
research into the impact of HAART on neurocognitive function utilising prospective 
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cohort studies in this region is needed, as well as more detailed investigation into the 
impact of HAND on everyday function in this population.  
 
Given the high rates of HAND, and indeed, HAD- the most severe form- it is key to 
better understand mechanisms of disease. In addition to the demographic, clinical 
and laboratory measures reported in this chapter, an investigation into other possible 
associated factors may shed light on the very high prevalences we found. The 
apolipoprotein E (APOE) allelic variants- in particular the E4 variant- have been well-
documented to occur more frequently in people who develop Alzheimer’s disease- a 
common dementia of old-age. Studies of APOE to date in people living with HIV 
(PLWH) have yielded some inconsistent findings. The relevance to South Africa, is 
that given our high rates of HAND (and HAD), should a higher frequency of the 
APOE4 variant be found in PLWH with HAD, it affords an opportunity to investigate 
disease mechanisms related to APOE4 (for example, vascular and metabolic 
factors), and to consider adjuvant treatments related to protein products of APOE4. 
Screening for APOE4 has not been regarded as a cost-effective strategy in 
Alzheimer’s disease, as the E4 variant is not predictive of dementia, rather it is a 
vulnerability factor. The exploration offered in the next chapter therefore builds on a 
model of neurocognitive disease vulnerability, involving genetic, socio-demographic 
and disease-related variables.
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Table 1. Demographic and clinical characteristics of the sample 
characteristic HIV+ participants HIV-negative participants 
Mean age (SD) 29.5 (3.65) 25.28(5.58) 
Women (%) 126 (74) 32 (64) 
Years of education (SD) 10.06 (1.85) 10.82 (1.64) 
Speak isiXhosa (%) 151 (88.8) 42 (84) 
CD4 count 181 (118) --  
Body Mass Index, mean 
(range) 
25.13 (48.04-17.64) --  
Haemoglobin, mean 
(range) 
11.39 (7.7-14.6) --  
Serum iron, mean (range) 11.40 (3.6-26) --  
Total protein, mean 
(range) 
93.61 (5.9-120) --  
Albumin, mean (range) 38.74 (24-49) --  
B12, mean (range) 333.68 (34-994) --  
Serum folate, mean 
(range) 
1587.04 (191.4-3676.4) --  
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Table 2. Demographic and clinical variables stratified by AAN category 
 Neurocognitive disorder category  
  Normal ANI MND HIV-D statistical value 
No (%) 40 (23.5) 15 (8.8) 72 (42.4) 43 (25.3)  
      
Demographics           
Women, no (%) 33 (82.5) 11 (73.3) 53 (73.6) 29 (69.1) Fisher's exact= 0.551 
Left handed, No (%) 35 (87.5) 14 (93.3) 66 (91.7) 39 (90.7) Fisher’s exact= 0.903 
Language isiXhosa, no (%) 34 (85) 14 (93.3) 63 (87.5) 40 (93) Fisher’s exact= 0.203 
Age, median (IQR) 30.5 (27.5-32) 28 (25-31) 28.5 (26-32) 31 (28-33) chi-sq=8.420, p=0.038 
Education, median (IQR) 11 (11-12) 9 (9-11) 10 (9-11) 10 (8-11) chi-sq=18.215, p=0.0003 
      
Medical           
CD4, median (IQR) 172 (126-190) 205 (148-235) 174.5 (116.5-236.5) 139 (97-182) chi sq=7.76, p=0.0512 
Peripheral neuropathy, no 
(%) 
37 (64.86) 15 (26.67) 69 (60.87) 39 (61.54) Fisher’s exact= 0.072 
AUDIT 0 (0) 1 (0) 2 (0) 3 (0) chi sq=0.925, p=0.815 
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CES-D 0 (0) 1 (0) 2 (0) 3 (0) chi sq=1.000, p=0.815 
BMI, median (IQR) 24.69 (22.68-28.72) 19.37 (18.8-21.3) 23.81 (21.81-26.44) 24.44 (21.03-28.12) chi sq=6.179, p=0.103 
HB, median (IQR) 10.9 (10.5-12.1) 9.05 (7.7-10.04) 11.7 (10.9-12.1) 11.2 (9.05-13.05) chi sq=3.727, p=0.291 
serum iron, median (IQR) 13 (8-18.6) 9.3 (9.3-9.3) 8.35 (5.9-10.2) 9.65 (9.5-15.3) chi sq=3.980, p=0.263 
total protein, median (IQR) 91 (87.5-97) 98 (98-98) 92.5 (88-100) 94.5 (84.5-109.5) chi sq=1.127, p=0.77 
Albumin, median (IQR) 40 (38-44) 42 (42-42) 40 (35-42) 37 (32-42) chi- aq=3.204, p=0.369 
serum B12, median (IQR) 288 (223-377) 306 (244-324) 299 (202-391) 306 (227-455) chi sq=1.058, p=0.787 







chi sq=2.448, p=0.485 
 
Key: AUDIT- Alcohol Use Disorders Identification Test; CES-D- Centers for Epidemiological Study- Depression scale; BMI- body mass index; HB- haemoglobin;   
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It is not known whether apolipoprotein ε4 is associated with HIV-associated dementia 
(HAD) in a South African population, where HIV clade C is predominant.  ApoE 
genotyping was performed on 144 participants in a larger study of HIV associated 
neurocognitive disorders (HAND).  There was a lower frequency of the ε2 and ε3 
alleles in the HIV positive group, compared to a group of 300 community-based 
newborn infants.   There were no differences in ApoE genotype across different 
categories of HAND. The ε4 allelic variant was less common in individuals with HAD, 
than in those without HAD.   Our findings suggest that the ε4 allelic variant in HIV 
positive individuals is not associated with the development of HAD in Southern 
Africa.  




In this chapter, I present data on the allelic frequency of apolipoprotein (APOE) allelic 
variants in a community sample of infants from the Western Cape, and then compare 
these to those found in our HIV positive sample. In a model of neurocognitive 
disease, it would be expected – as in Alzheimer’s disease- that older persons are 
more vulnerable to developing dementia. In chapter 4, we found that older age was 
associated with higher rates of HIV-associated dementia (HAD). However, the clinical 
significance of this is unclear, given that our sample was purposively selected as 
being younger than 35 years of age in order to exclude potential neurodegenerative 
diseases of old age. It is possible, however, that APOE4 represents a vulnerability 
factor, that together with HIV infection could lead to higher rates of HAD.  
 
Apolipoprotein E (ApoE) is a protein involved in lipid metabolism in both peripheral 
tissue, as well as the central nervous system. It has three major allelic variants: ε2, 3, 
4. ApoE allelic variants occur with different frequencies across different ethnicities, in 
particular between individuals of European and African descent [1]. The ApoE4 allelic 
variant is thought to be commonest in African populations. In one epidemiologic 
review, the frequency of ε4 in Caucasian samples (defined as the number of ε4 
alleles in the total sample) ranged from 0.082 to 0.194, while in a Nigerian sample, 
the reported frequency was 0.310 [2]. In a study of the Khoi San population of 
Southern Africa, an allelic frequency of 0.37 was reported [2,3]. The higher frequency 
of ApoE4 in individuals of African ethnicity may have substantial implications for the 
frequency of neurodegenerative conditions in this setting.   
 
The ε4 allelic variant has been shown to increase the risk of developing both 
Alzheimer’s disease (AD) and certain brain disorders [4,5]. ApoE4 is thought to be 
involved in the consequences of abnormal lipid metabolism (such as 
atherosclerosis), as well as in several inflammatory pathways in the central nervous 
system (CNS) [2]. The latter pathways include increased microglial responses, 
oxidative stress and the production of nitric oxide [6-8] In AD, the ε4 allelic variant is 
associated with an increased deposition of amyloid plaques [9] Amyloid production is 
in part mediated by cytokines secreted from activated microglia, a process which 
may be accelerated in carriers of the ε4 allele [10]. Microglial activation may also 
occur in infections of the CNS infections, such as HIV. The combined effect of certain 
ApoE allelic variants and HIV infection may result in an additive neurodegenerative 
effect [11].  
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There are similarities between neurodegeneration in HIV-associated dementia (HAD) 
and that of AD. For example, the amyloid precursor protein has been reported in 
those with HIV encephalitis [12]. Other clinical-pathological studies among older 
subjects with HIV infection have identified an association with CNS plaques and 
elevations of CSF amyloid beta [13,14]. In one report it was noted that a genetic 
variant of tumour necrosis factor alpha is associated with HAD (reported as AIDS 
dementia complex) [11]. Clinical studies of the associations between ApoE and HAD 
have produced conflicting results, with some reporting increased risk for HAD and 
peripheral neuropathy and others describing no association [10,15]. Some have 
noted that the ApoE4 genotype together with advancing age confers an increased 
risk for HAD [16,17].  
 
To date most studies of ApoE and HIV-associated neurocognitive disorders have 
been conducted in high income countries where HIV clade B predominates. It has 
been proposed that the different HIV clades exert different neurotoxic effects via a 
functional difference in the transactivator protein (tat) [18]. Clinical reports from India 
and South Africa suggest that HAND may be as common in regions where clade C 
predominates [19,20]. In these populations, HAND may then involve mechanisms of 
neurotoxicity other than those mediated by tat. The possible role of other correlates 
of HAND, such as ApoE4 requires further study. Evidence for the interactive effect of 
age with ApoE4 on neurodegeneration suggests that this variant is associated with 
an accelerated disease course and progression to death [17,21] These data are 
supported by the fact that while HAD has been linked to a higher frequency of ε4 in 
some reports, this genotype occurs less often in older individuals, even when 
controlling for ethnicity [21] 
 
In this study, we sought to establish the distribution and frequency of ApoE allelic 
variants in a South African HIV positive clinic population well characterized with 
respect to HAND status. In particular we evaluate potential associations between 
ApoE4 and HAD. We hypothesized that the ApoE4 allelic variant would occur at 
higher frequencies similar to that reported in other African populations, and that this 
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From a larger primary study, we invited 283 HIV-infected individuals at three primary 
health care centres in poor communities in Cape Town, South Africa to participate 
from February 2008 through August 2009 [22]. Of these, 144 attended two full study 
visits during which detailed a socio-demographic, medical and neuropsychological 
assessment were conducted, and laboratory measures (including genotyping) were 
completed. Primary reasons for this loss to follow-up included financial constraints, 
casual employment on clinic days, migration between cities and the need to attend 
other clinic appointments. Individuals included in this study ranged from 18 through 
40 years in age.  All were naïve to highly active anti-retroviral therapy (HAART). 
Cases were excluded if they had a severe psychiatric disorder, recent history of 
substance (including recent alcohol) abuse or other significant neurological disorder. 
Control data for neuropsychological testing was obtained from 50 HIV negative 
participants. These were recruited from Voluntary Counseling and Testing services at 
the same primary care clinics. Other than being HIV negative, as confirmed by a 
recent rapid HIV test and confirmatory serological test, inclusion and exclusion 
criteria were identical to HIV positive participants.  
 
Participant CD4 cell counts were obtained from the clinic records. Although clade 
sequencing was not available on this sample, previous reports have noted that 89% 
of infected individuals in Cape Town area are infected with clade C virus [23] 
Furthermore, although hepatitis C status was not tested, the prevalence of hepatitis 
C in South Africa is extremely low [24]  
 
Background population prevalence of ApoE genotype was obtained from a sample of 
300 infants born to isiXhosa speaking mothers in an area of Cape Town where the 
majority of the clinical sample above was drawn. The blood from these infants was 
drawn from 2002 through 2004 and stored in accordance with a previously approved 
Research Ethics Committee submission, in order to allow for analysis of background 
prevalence of genes under study. The HIV serostatus of this group was not known. It 
was assumed to reflect the background population prevalence in newborns at the 
time. According to local surveys, the seroprevalence amongst mothers in this 
community in 2006 was 15% [25]. With untreated mother-to-child transmission rates 
of 10-30%, we estimated the seroprevalence in this infant sample to be between 1.5-
5%. This rate was felt to be unlikely to affect this data. 
 
We obtained written informed consent from all included participants, including 
separate consent for genomic analysis. Approval to conduct the study was obtained 
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from the Research Ethics Committee of the Faculty of Health Sciences, University of 
Cape Town, and from the relevant health authorities.  
 
Neuropsychological test battery 
A neuropsychological testing battery assessed specific domains of attention, 
concentration, language, learning, memory, psychomotor speed and executive 
function. We translated the instructions and content of all instruments into local 
languages- isiXhosa and Afrikaans. The instructions were back-translated for fidelity. 
The battery comprised the following tests: Attention (the Mental Alternation Test and 
the Mental Control Test), learning and memory (the Hopkins Verbal Learning Test 
and the Brief Visuospatial Memory Test), motor (Finger tapping  and Grooved 
Pegboard- both dominant and non-dominant hands), psychomotor speed (Trail-
Making part A, Color Trails 1 and Digit Symbol coding) executive function (Colour 
Trails 2, the Stroop Colour Word test, the Wisconsin Card-Sorting Test and the Rey 
Complex Figure), and language (Category fluency animals and  Category fluency 
fruit and vegetables). Information regarding selection and adaption of the battery is 
contained in the “Introduction” to the thesis on page 15. 
 
Determination of neurocognitive disorder status 
We used the above neuropsychological test battery, together with scores from the 
medical assessment and self-reported functional assessment to classify participants 
into one of four HAND categories, based on the updated American Academy of 
Neurology criteria [26]: no impairment, asymptomatic neuropsychological impairment 
(ANI), mild neurocognitive disorder (MND) and HIV-associated dementia (HIV-D). 
Using the modified AAN classification, participants who scored >2 SD below the 
control-derived means cut-offs on at least two domains of function were rated as 
having HAD; those who scored between 1.0 and 2 SD on two domains of function, or 
>2 SD and 1-2 SD, were rated MND or ANI, depending on their loss of function. The 
final classification was conducted by a consensus panel comprising two HIV 
neuropsychiatrists (JJ, JH) and a neurologist (MC). 
 
Genotyping 
DNA was isolated by standard procedures and the method of Hixson and Vernier 
was used for Apolipoprotein E (ApoE) genotyping [27]. We did not include genotyping 
data of the HIV negative control adults, as this was available on only 10 participants. 
 
Statistical analysis  
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Data were analyzed using STATA 10.0 (Stata Corporation, College Station, Texas, 
USA). In order to establish whether the allelic frequency was randomly distributed in 
the sample of control newborns and the HIV positive participants, we conducted an 
analysis of the Hardy-Weinberg equilibrium (HWE). This principle asserts that mating 
is random, there is no migration or inbreeding and no selective survivorship [28]. 
Calculation of the HWE allows the investigator to report with some confidence that 
external factors have not altered the gene frequency in the population to any 
significant degree, and therefore that the observed frequency is not an artifact of 
these external factors. The allelic distributions between the newborn and HIV positive 
adult groups were compared using exact statistics, while allelic frequencies were 
calculated to include 95% binomial confidence intervals in addition to chi-squared 
tests. Similarly, we compared allelic distributions across HAND categories. Finally, 
we compared HAD and non-HAD groups with respect to the presence of the ε4 allelic 
variant using a table exact statistic.   
 
RESULTS 
A total of 144 HIV positive participants were included in the analysis. The majority 
were women (74%), isiXhosa speaking (88%) and had a median CD4 cell count of 
168 (IQR 115-199). The median CD4 counts for the categories of HAND were 182 
(IQR 148-191) for non-impaired, 181 (IQR 146-235) for ANI, 180 (IQR 128-241) for 
MND and 139 (IQR 75-184) for HAD. The mean age was 29.5 (SD 3.65) and level of 
education was 10 years (SD 1.85) (table 1).  
The distribution of ApoE alleles were found to be in Hardy-Weinberg equilibrium 
(HWE) for both the group of controls, as well as the HIV+ participants. Using an 
Exact statistic the probability of the two groups not being in HWE was 0.68 and 0.55 
respectively. 
 
Apolipoprotein ε in HIV positive group and the general population 
The distribution of ApoE allelic combinations for HIV positive study participants and a 
newborn population-based sample for comparison is presented in table 2. When we 
compared the overall genotype distributions between 2 groups, we found significant 
differences between the genotypes (two-sided exact p-value = 0.042). The ε2/ε2 
allelic combination was significantly less frequent in the HIV positive group than the 
newborn controls. 
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The allelic frequencies between the HIV positive and the newborn groups are 
presented in table 3. We found that the ε2 and ε3 alleles differed significantly (chi-
squared  = 12.2   df = 2, p = 0.002), with a lower frequency of the ε2 and ε3 alleles in 
HIV positive adults than newborn controls.  
 
Apolipoprotein ε and HAND 
There were no differences in the allelic distributions of ApoE across different 
categories of HAND (overall exact p-value=0.66), nor were there differences in CD4 
count for the ApoE genotypes (p=0.14).  The relationship between ε4 status (having 
one or more ε4 allele) was compared to participants with and without HAD (table 5). 
In this analysis, there were significantly fewer individuals with ε 4 in the HAD group 
(chi-squared, df =1, p=0.03, odds ratio with 95% C.I.  0.41 (0.17-0.99)). 
 
DISCUSSION 
We report the first study, to our knowledge, evaluating the relationship between ApoE 
genotype and HAND in southern Africa. In this study, the allelic frequency of the ε4 
allelic variant in both the community-based newborns and the HIV positive adults was 
similar to reports of other African populations. The frequency of the ε2 allelic variant 
was significantly lower in the HIV positive adults compared to newborns. There were 
no differences in ApoE genotype and category of HAND. We did notea significantly 
lower frequency of the ε4 allelic variant in adults with HAD, compared with those 
without HAD.  
 
In this sample, among isiXhosa speakers, we found a high frequency of the ε4 allelic 
variant amongst newborns, as well as HIV positive adults (0.302 and 0.297 
respectively). The relatively high frequency of the ε4 variant is in keeping with other 
studies of African populations, where frequencies of Apoε4 of 0.31 and 0.20 have 
been found, and confirms that Apoε4 is more common in this ethnic group than in 
non-African groups [17,29]. In a study of the indigenous Khoi San population in 
Southern Africa, a slightly higher frequency was found (0.37) [3] A similar frequency 
of Apoε4 was found also in the control sample (0.30). The implications of this high 
frequency of ε4 are for increased rates of ε4-related neurodegenerative diseases, 
including HAD. This is of especial relevance in a regions with a very high HIV 
seroprevalence and an ageing population [17,30]  
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In addition, we found that the ε2/ε2 genotype occurred significantly less frequently 
among HIV positive adults compared with community-based newborns, while the 
individual ε2 and ε3 allelic variants specifically were less frequent in this group.  We 
noted also the distribution of ApoE alleles compared with other studies suggests 
higher frequencies of the 2/3 and 2/4 combination, and a lower frequency of the 3/3 
combination [2,3,16] Some have proposed that the ε4 variant is associated with 
increased rates of HIV acquisition [31]. Should this be the case, then a putative 
“biological protective” factor may be able to be identified in ε2/ε2 carriers. In the 
absence of ApoE genotype of the adult HIV negative controls, and survival data on 
our HIV positive group, we are unable to draw conclusions regarding the role that 
ApoE allelic variants might have on  acquisition of HIV infection in our population. 
Larger cross-sectional and sero-conversion studies are needed to provide evidence 
for this link. 
 
In this sample of young adults entering HIV care, we report that there were no 
differences in allelic distributions across HAND categories. However, we did find a 
significantly lower frequency of the ε4 allelic variant in individuals diagnosed with 
HAD, compared with those without HAD. Our sample size was likely too small to 
detect differences in genotype across the four groups. In our two-by-two analysis, we 
found a significantly lower frequency of ε4 status among HIV positive adults with 
HAD. This finding is in contrast to that of Corder and colleagues who found that in a 
sample of 44 HIV+ participants followed prospectively from around the time of sero-
conversion, mild suspected dementia was nearly twice as frequent in the ε4 bearing 
individuals [32]. Our sample was too small to separate ε4 status in hetero- and 
homozygous groups, although others have noted that a dose-dependent relationship 
of ε4 with the development of AD has been shown [17,30]. Should a larger study 
confirm non-association, as opposed to non-survival, then it might suggest that the 
pursuit of APOE as a vulnerability factor in the development of HAND would not be a 
worthwhile one. 
 
Our findings are consistent with the report of Dunlop and the younger group in the 
Valcour study [15,16]. Our finding that the ε4 allelic variant was negatively associated 
with HAD could be explained by the relatively small sample size, or it could suggest a 
non-association between ε4 status and the development of HAD. In addition, while 
there is controversy regarding ε4 as a risk factor for Alzheimer’s disease in African 
Americans, our findings suggest that it is not associated with HAD in black Africans.  
Further conclusions regarding the effect of ε4 on survival require follow-up survival 
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data. The negative impact of ε4 has been proposed by the Valcour group. A 
longitudinal study design would be needed to provide data for this explanation. 
 
Our study was limited by relatively small numbers of participants and by the absence 
of other data on vascular risk factors. Nonetheless, we believe that our findings 
warrant scrutiny, given the burden of disease of infection with clade C HIV and the 
frequency of ApoE4. Many of these issues would be clarified by larger prospective 
cohort studies where recently diagnosed isiXhosa speakers are genotyped. To our 
knowledge, this is the first study of ApoE genotype in a well-characterised group of 
HIV+ individuals with predominantly clade C HIV about to commence HAART. These 
findings are of relevance given the high prevalence of HIV in Southern Africa, the 
growing evidence that clade C HIV may be as neurotoxic as other clades, and the 
changing phenotype of HAND in the era of HAART. In addition, we noted that of the 
283 participants recruited at site, 170 attended the full assessment visit. This could 
have introduced a selection type bias. We felt that early logistic problems, such as 
financial constraints and accessibility- which were late addressed- most likely 
accounted for this drop-out. In addition, we noted that if participant factors such as 
neurocognitive disorder were at issue, then our findings would under-report the 
prevalence of these disorders. 
 
The investigation into the APOE genotype represents one possible genetic pathway 
of disease development; others were not explored in this thesis. In addition to 
exploring possible biologic and socio-demographic vulnerability factors as reported in 
this and the previous chapter, clinicians in busy settings need tools with which to 
uncover the problem of HIV-associated neurocognitive disorders (HAND). This 
addresses the need for treatment. In the next chapter, I turn to establish whether a 
brief screening tool, validated in Uganda, performs adequately in South Africa. Such 
tools may empower non-neurologists or psychologists to quickly establish whether 
severe HAND is present, and to offer the best-evidence treatment to date: HAART.  
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Table 1. Demographic characteristics of HIV positive participants and HIV negative 
adult neuropsychology controls 





Mean age (SD) 29.5 (3.65) 25.28(5.58) <0.001 
Women (%) 106 (74) 32 (64)  
Years of education (SD) 10.02 (1.85) 10.82 (1.64) 0.642 
Speak isiXhosa (%) 127 (88.2) 42 (84)  
CD4 count 188 (118) --  --  
AAN-defined HIV-D (%) 41 (28.4%) -- -- 
 
 




Table 2. Allelic distributions for newborns and participants. 
 





22 2 (1) 18 (6) 0.028 
23 21 (15) 52 (17) 0.497 
24 8 (6) 33 (11) 0.079 
33 50 (35) 78 (26) 0.073 
34 49 (34) 90 (30) 0.444 
44 14 (10) 29 (10) 0.999 
Total 144 300  
 
Table p-value (exact) 0.042 
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Table 3. Allelic frequencies for control newborns and HIV positive participants 
 
          300 newborns            144 HIV positive adults  
alleles       n frequency (95% CI)         n frequency (95% CI)  p value 
ε 2     121 0.202  (0.170 - 0.236) 35     0.114  (0.081 - 0.155)  0.001 
ε 3     298 0.497  (0.455 - 0.537) 180     0.588  (0.531 - 0.643)   0.01 
ε 4     181 0.302  (0.265 - 0.340) 91     0.297  (0.247 - 0.352)  0.876 
total     600  288      
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Table 4. Allelic frequencies of HIV positive participants across neurocognitive 
disorders 












22 1 (50%) 0 0 1 (50%) 0.47 
23 2 (9.5%) 2 (9.5%) 8 (38.1%) 9 (42.9%) 0.381 
24 2 (25%) 1 (12.5%) 3 (37.5%) 2 (25%) 0.999 
33 7 (14%) 9 (18%) 21 (42%) 13 (26%) 0.31 
34 12 (24.49%) 4 (8.2%) 19 (38.9%) 14 (28.6%) 0.627 
44 5 (35.7%) 2 (14.3%) 5 (35.7%) 2 (14.3%) 0.351 
Exact p-value for table, 0.66 
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Table 5. Comparison between ε4 status with HAD and non-HAD clinical groups. 
                                HIV positive   n = 102 
  with 4 allele   without 4 allele      total 
  HAD     18                 33                    51         
  No neurocognitive 
disorder 
    29                 22                    51         
            total      47     55 102 
 
Exact p-value for table, 0.029 (ie, 18/51 is significantly lower than 29/51) 
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HIV-associated neurocognitive disorders (HAND) remain prevalent, especially in 
regions like South Africa where HIV prevalence is high but access to anti-retroviral 
treatment (ART) is limited. The incidence of HIV dementia (HAD) has been halved 
with the use of ART, but the prevalence remains high. Appropriate brief screening 
tools to screen for HAD are needed in order to facilitate treatment initiation. The 
validity of the International HIV Dementia Scale has not been established in a region 
where infection with HIV clade C is predominant. The International HIV Dementia 
Scale (IHDS) was administered together with a detailed neuropsychological test 
battery to 163 HIV positive individuals who had not received ART and who were 
attending primary care HIV clinics. The validity of the IHDS was established using a 
receiver operating characteristic (ROC) analysis. HIV+ individuals performed worse 
than HIV- controls on the IHDS and a range of neuropsychological tests. 
Neuropsychological tests discriminated well across HAND categories for HIV+ 
individuals.  In ROC analysis, the IHDS returned an area under the curve of 0.73, 
with a sensitivity of 85% and specificity of 54% at a cut-off score of 10. Individuals 
with HAD, who screened negative on the IHDS, performed poorly on some tests of 
executive function. These data suggest that the IHDS adequately screens for HAD in 
South Africans infected with predominantly clade C HIV.  Variable performance in 
neuropsychological testing may account for false negative screens. The inclusion of 
brief tests of executive function in a screening battery should be considered.  





Clinicians in busy clinic settings, especially in South Africa, where throughput of 
patients is enormous, seldom consider neurocognitive issues in their patients unless 
they are overt. In chapter 4, I presented data based on detailed neuropsychological 
and clinical assessment of this patient group. This approach is not feasible in 
practice, and so in this chapter, I present data supporting the potential use of the 
International HIV Dementia Scale. Then, even patients with CD4 cell counts >200 
cells per ml would be eligible for HAART under current South African treatment 
guidelines. 
 
HIV associated neurocognitive disorders (HAND) remain highly prevalent, occurring 
in an estimated 50% of people living with HIV/AIDS, depending on disease stage [1-
3]. HAND remain common in both the developed and developing world. The one-year 
incidence of HIV dementia (HAD), the severest and most debilitating form was 
reported in 25% of individuals in two separate North American cohorts, irrespective of 
the use of anti-retroviral treatment (ART) [4]. Detailed studies of HAND globally are 
few, but similar figures have been reported in India, China and South Africa  [5-7]. 
The advent of ART has substantially altered the nature of these disorders, although 
they are now known to persist despite its widespread use [3,8]. HAD results in a 
number of important adverse outcomes, including increased mortality, decreased 
adherence to ART, and decreased employment  [4,9].  
Formal neuropsychological testing remains the gold standard of diagnosis of HAND 
[10]. While most studies report a typical pattern of neuropsychological impairment, 
involving executive functions, motor functions, speed of processing and impaired 
recall, there is evidence to suggest a wider variability of deficits [11]. 
Neuropsychological deficits in HAND are thought to track the brain regions primarily 
involved affected by HIV, namely the sub-cortex and striatum [12]. Accordingly, 
impairments of executive dysfunction, motor slowing, impaired speed of processing 
and impaired memory recall are regarded as characteristic of HAND [10]. 
Neuropsychological test batteries need to sample across a number of domains in 
order to detect impairment. Furthermore, the application of neuropsychological 
testing is well known to be dependent on a range of factors including age, culture, 
language, level of education, and the presence of co-morbid neurologic problems, 
such as substance abuse [3,13]. 
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A number of brief screening tools have been proposed for use in primary health care 
and resource limited settings. These include the HIV Dementia Assessment, HIV 
Dementia Scale (HDS) and the International HIV Dementia Scale (IHDS) [14-16]. 
The IHDS has been validated in both the USA and Uganda [15]. Both the HDS and 
IHDS were found to be useful tools in a smaller study in Canada [18]. The 
development of an appropriate screening tool for HAND first requires detailed 
neuropsychological characterisation of impairments which may be affected by 
regional differences, such as culture, language or clade differences [3,17]. 
Differences in the neurotoxic effects of the different HIV clades have been proposed, 
although early clinical studies suggest that clade C, common in South Africa, may 
produce high rates of HAND [19]. The validity of a brief screening tool would then 
need to be validated across different settings.  
  
A number of potential issues need to be considered when making use of screening 
tools. These include the need to be brief, easy for non-specialists to administer, and 
adaptable for use in cross-cultural settings. Also, a screening tool should be both as 
sensitive and specific to HAND, taking into account neuropsychological functions 
commonly thought to be affected by HIV. The IHDS includes three sub-tests: a non-
dominant finger-tapping test, a non-dominant Luria hand sequence, and a four-word 
recall test. The IHDS was validated in an American and Ugandan sample, and was 
found to have a sensitivity and specificity in the Uganda sample of 80% and 55% 
respectively [15]. More recently, the IHDS was compared to a brief 
neuropsychological battery in Canada, where a receiver operating characteristic 
(ROC) analysis generated an area under the curve of 0.74 [18]. The authors reported 
that the HDS and IHDS were relatively efficient in diagnosing HAND, with the IHDS 
displaying a sensitivity and specificity of 76.9% and 65% respectively [18]. Further 
studies in regions of high HIV prevalence and unique clade sequencing are needed.  
In the present study we aimed to describe the performance of the IHDS against 
categories of HAND defined by the updated American Academy of Neurology criteria. 
We examined scores from a detailed neuropsychological battery in a sample of clade 
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This study formed part of a larger investigation of HIV-associated neurocognitive 
disorders in Cape Town, South Africa. In summary, 283 HIV-infected individuals at 
three primary health care centres were invited to participate from February 2008 
through August 2009. Of these, 163 attended two full study visits during which 
detailed socio-demographic, neuromedical, neuropsychological, and laboratory 
measures were administered. The evaluations took between two and three hours. 
Details of this characterization have been previously published [19]. Of the 163 
individuals characterized, 97 received the IHDS in addition to the above 
assessments, and these were included in this analysis. Included individuals ranged 
from 18 through 40 years of age, and were assessed prior to commencing treatment 
with ART. Potential participants were excluded if they had a severe psychiatric 
disorder (such as schizophrenia or bipolar disorder), recent history of substance 
abuse or significant neurological disorder (such as epilepsy or significant head injury 
with loss of consciousness more than 30 minutes).  
 
All participants who met study criteria and agreed to participate provided written 
informed consent.  Approval to conduct the study was obtained from the Research 
Ethics Committee of the Faculty of Health Sciences, University of Cape Town, and 
from the relevant clinic authorities.  
 
Neuropsychological test battery 
A neuropsychological test battery was administered to all participants to assess 
specific domains of neurocognitive function. The battery comprised tests of attention 
(the Mental Alternation Test (MAT) and the Mental Control Test (MCT)), learning and 
memory (the Hopkins Verbal Learning Test (HVLT) and the Brief Visuospatial 
Memory Test (BVMT)), motor (Finger Tapping (FT) and the Grooved Pegboard Test 
(GPT)), psychomotor speed (Trail Making Test part A (TMTA), Color Trails Test 
1(CT1) and Digit Symbol-Coding (DSC)), executive function (Color Trails Test 2 
(CT2), Stroop Colour-Word test (SCW), Wisconsin Card-Sorting Test (WCST), and 
category fluency- including an animal list and a fruit and vegetable list).  
 
Control data for neuropsychological testing was obtained from 93 HIV-negative 
participants. These participants were recruited from Voluntary Counseling and 
Testing services at the same primary care clinics. We liaised with lay counsellors at 
clinics to obtain suitable participants who had been both counselled and tested, and 
who would be willing to be approached for the research study. Other than being HIV 
negative, as confirmed by a recent rapid HIV test and confirmatory serological test 
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done at the study visit, inclusion and exclusion criteria were identical to those applied 
to HIV-positive participants. The CD4 cell count was obtained from the clinic records. 
Data from the 93 HIV-negative controls were used to generate z-scores for 
establishing the degree of impairment for each test. No published norms are currently 
available in South Africa, and as most participants spoke isiXhosa, we elected to 
generate control data from similar community participants. 
 
The IHDS was administered by medical officers trained in HIV neuropsychiatry. A 
uniform approach was ensured through the study leader. The IHDS was 
administered during the same visit as the study neuromedical assessment.  
 
Determination of neurocognitive disorder status 
We used the above neuropsychological test battery, and an evaluation of functional 
assessment (the Patients’ Assessment of Own Function (PAOFI) and the Quality of 
Life and Enjoyment Satisfaction Questionnaire (QLESQ)), to classify participants into 
one of four HAND categories, based on the updated criteria published by Antinori 
and colleagues [20]: no impairment, asymptomatic neuropsychological impairment 
(ANI), mild neurocognitive disorder (MND), and HAD. Individuals who scored more 
than two standard deviations (SD’s) below the mean on at least two domains of 
function, and were noted to have significant functional impairment on self-report, 
were classified as having HAD. Those who displayed impairment between one and 
two SD’s, were classified either as MND or ANI, depending on the presence or 
absence of functional impairment. The remaining participants were classified as non-
impaired. The final classification was conducted by a consensus panel comprising 
two HIV neuropsychiatrists and a neurologist. 
 
Statistical analysis 
Data were analysed using STATA 11 (Stata Corporation, Texas, USA). The HIV-
positive and HIV-negative groups were compared with respect to age, level of 
education and neuropsychological test characteristics using unpaired t-tests, and 
with respect to gender distribution using a Fisher exact test. The HAND categories of 
HIV-positive participants were compared using Kruskal-Wallis tests for differences 
between medians of multiple groups. The difference between the means of the HAD 
group and the remaining participants were compared using an unpaired t-test. The 
ability of the IHDS to predict HAD was established using a receiver operating 
characteristic curve, and cut-off scores calculated from this. Correlations between the 
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IHDS total score and sub-test scores were calculated for each neuropsychological 
test, and r-values reported. P-values were regarded as significant at the 5% level. 
 
RESULTS 
The demographic characteristics of the HIV-negative and HIV-positive groups are 
shown in Table 1. There were significant between-group differences in terms of age 
and level of education, but not gender distribution. There were also significant 
between-group differences in performance on a number of neuropsychological tests 
within each domain. Regarding the screening test (IHDS), the only test for which 
there was no significant between-group difference was the Luria sequence non-
dominant hand (p=0.94). HIV-positive participants performed significantly more 
poorly than HIV-negative controls on all other neuropsychological tests, other than 
the MAT (p=0.75), CT1 (p=0.61) and CT2 (p=0.35).  
 
The neuropsychological test performance characteristics of the HIV-positive 
participants classified into HAND categories is shown in Table 2. In this analysis, we 
found significant between-group differences on all neuropsychological tests, except 
for the FT non-dominant sub-score of the IHDS (p=0.10) and the MAT (p=0.06). 
Participants with HAD had lower mean total IHDS scores than the remaining 
participants, with means of 9.69 (SD=1.97) and 10.67 (SD=1.11) respectively 
(p=0.00). 
 
Correlations between the IHDS total and sub-test scores, on the one hand, and each 
neuropsychological test, on the other, are shown in Table 3. We identified significant 
correlations between the IHDS total score and the FT-ND, HVLT, BVMT, MC, CT1, 
CT2 and category fluency (fruit and vegetables ) z-scores.  The CT1 was significantly 
correlated with all components of the IHDS. 
 
The receiver operating characteristic curve of the IHDS using the HAND categories 
of HAD together with MND versus other categories as gold standard is shown in 
Figure 1. The area under the curve was 0.71. The varying cut-off scores for the IHDS 
are presented in Table 4. At a cut-off score of ≤10, the sensitivity and specificity of 
the IHDS was 53 % (95% CI 41-66) and 80 % (95% CI 63-93) respectively. Using a 
cut-off of ≤11, the sensitivity and specificity of the IHDS was 86 % (95% CI 75-93) 
and 32% (95% CI 17-51) respectively.  
 
DISCUSSION 
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In South Africa where HIV is highly prevalent, and rates of severe HAND are in 
excess of 50%, access to a screening tool for cognitive impairment has both clinical 
and research relevance. In this study we identified that the IHDS performs 
adequately when used to diagnose severe HAND (including HAD and MND). We 
utilized a detailed neuropsychological battery which was sensitive to differences 
between HIV negative and HIV positive controls. When we compared IHDS and 
neuropsychological test performance in the HIV positive participants across 
categories of HAND, we observed that the battery discriminated well across different 
groups, and for a number of test domains. In a receiver operating curve analysis 
using a cut-off score of ≤11, the IHDS was 53% sensitive and 80% specific. The 
IHDS correlated moderately with individual neuropsychological tests. 
 
The ROC analysis revealed that the IHDS performed reasonably well, although a cut-
off score of ≤11 provided a better sensivity. When we used a cut-off score of ≤10, the 
sensitivity and specificity was 53% and 80% respectively. It may be more beneficial 
to retain the higher sensitivity and therefore use the cut-off of ≤11 rather than ≤10, in 
order not to miss cases. In the original description of the IHDS, cut-offs of ≤10 
yielded sensitivities of more than 80%, with moderate specificity [15]. The 
performance of the grooved pegboard test non-dominant has previously been 
reported to yield a sensitivity and specificity of 71% and 46% respectively, using a 
cut-off of 1.5 SD below adjusted means. Others have reported sensitivity and 
specificity of 77% and 65% respectively. The IHDS therefore could be useful tool, 
although clinicians in South Africa may need to consider using the higher cut-off 
score of 11.  
 
HIV-positive individuals in this study performed worse than their HIV-negative 
counterparts on most tests of neuropsychological function, including the IHDS. Of 
note, there were no differences in performances on the hand sequence component of 
the IHDS, the MAT, CT1 and CT2 tests. Overall, then, our battery was sensitive to 
HIV-associated neuropsychological impairments. Of interest is that both groups of 
participants in our study performed better on CT1 and 2 than participants in Uganda 
[15]. This may be explained by lower levels of education in that study’s participants 
(9.7 for controls and 8.7 years for HIV-positive participants). In addition, in the 
Ugandan study, no differences in motor performance were reported. These included 
the GPT and timed gait tests, while in our study, we did find differences in this 
domain [15]. One possible explanation is that regional and clade differences account 
for these domain-specific differences. The HIV epidemic in Uganda is known to be 
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predominantly made up of clades A, D, and D, while in South Africa clade C is 
predominant [21]. Previous studies of participants with clade C HIV have also 
reported abnormalities on GP [23].  
 
The IHDS, together with individual neuropsychological tests, discriminated well 
between HAND categories. This suggests that these tests are suitable in 
differentiating different forms of HAND. The mean total IHDS score for individuals 
with HAD was 9.67, compared to 10.67 for other participants. In the group analysis, 
the finger-tapping test of the IHDS did not discriminate well across all categories, 
though the performance in the HAD group was worse than the other three groups 
(mean of 3.19, versus 3.64, 3.72 and 3.63 respectively; p=0.10). The finger-tapping 
test used in the battery, however, did discriminate well between the groups. An 
adapted brief screening tool might therefore include a more detailed finger-tapping 
test. 
 
The correlation between the IHDS total score and sub-test scores, on the one hand, 
and individual neuropsychological test scores, on the other, varied from weak to 
moderate. We expected the total IHDS score to correlate more strongly with non-
dominant hand performance on the GP-non dominant test, as reported by Sacktor 
and colleagues [15]. However, as noted above, this difference might be explained by 
regional and clade-specific differences in test performance. We also expected the 
IHDS finger tapping test to correlate more strongly with the similar 
neuropsychological test, but the results were weak. The IHDS recall test correlated 
moderately with the HVLT test. The weaker correlations that we found might be 
explained by differences in test internal construct validity and ecology being different. 
To date there has been little or no research describing construct validity of these 
neuropsychological tests in South Africa; and in isiXhosa speakers in particular. 
Further comments regarding the selection of the test battery may be found on page 
15 of the “Introduction”. Suggestions for further research are made in the 
“Conclusions” chapter.  
 
This study had several limitations.  First, our sample size was not very large.  We did 
not believe this is a significant weakness as we were able to identify statistically 
significant differences between groups in terms of cognitive status.   Secondly, while 
our group has taken care in translating and adapting the neuropsychological test 
battery to ensure its suitability for South Africans, we have not undertaken to 
establish construct validity. Thirdly, while we took care to train and supervise medical 
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officers administering the IHDS, we did not conduct inter-rater reliability 
assessments, and this might have influenced our results. The administrator of the 
IHDS and the full neuropsychological battery was not the same rater. 
 
We believe this study contributes to our knowledge about HAND in Southern Africa. 
Specifically, that neuropsychological impairment is frequent and severe in South 
Africa. Furthermore, the IHDS may be a useful screening tool, though efforts to 
understand the modest level of specificity requires further study. Individuals with HAD 
clearly perform worse on the IHDS, as well as on most tests included in our detailed 
battery as expected since performance on cognitive testing is utilized in the 
diagnostic classification. Nonetheless, as a brief tool, the IHDS performed well in 
comparison to the detailed battery and discriminated across different severities of 
HAND. Further research into refining the IHDS and incorporating it as a brief 
screening tool in to primary care is needed.  
In this chapter, I have reported on the performance of the IHDS. The use of this tool 
could improve detection through its use, as well as through awareness of the 
problem of severe HAND. As mentioned previously, the detection of HIV-associated 
dementia, even at higher CD4 counts affords the patient the possibility of initiating 
HAART. In the next chapter, I report on findings of a one-year follow-up of individuals 
who had initiated HAART in the Western Cape of South Africa.  
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Table 1. Demographic and neuropsychological characteristics of HIV- and HIV+ participants 
  HIV negative controls (n=93) HIV positive participants (n=96) P value 
Age 25.16 (5.15) 29.75 (3.67) 0.00 
Education 10.88 (1.28) 10.05 (1.77) 0.00 
Gender female (%) 58 (62.4) 76 (79.2) 0.79 
CD4 cell count  218.09 (150.57)  
Years since diagnosis  3.35 (2.04)  
IHDS total 10.89 (1.10) 10.29 (1.55) 0.01 
IHDS FT subscore 3.88 (0.36) 3.52 (0.79) 0.00 
IHDS hand sequence 
subscore 3.21 (0.88) 3.22 (0.92) 0.94 
IHDS 4-word recall 3.78 (0.59) 3.35 (0.91) 0.00 
FT non-dom 6.77 (1.71) 8.87 (2.08) 0.00 
GP non-dom 78.36 (12.54) 87.05 (25.46) 0.00 
HVLT recall 8.07 (2.07) 7.03 (2.09) 0.00 
BVMT recall 8.97 (2.92) 6.52 (3.50) 0.00 
MAT 16.47 (6.43) 16.76 (5.20) 0.75 
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Mental control 23.67 (5.93) 19.48 (5.62) 0.00 
Digit symbol 46.83 (14.62) 40.72 (13.18) 0.00 
TMTA 40.18 (16.31) 60.56 (32.41) 0.00 
Colour I 54.66 (21.10) 53.21 (16.93) 0.61 
Colour II 115.48 (50.98) 122.27 (48.47) 0.35 
Stroop C/W 33.66 (9.57) 27.91 (9.24) 0.00 
WCST per errors 31.92 (19.68) 45.34 (25.41) 0.00 
animal 15.80 (4.64) 13.27 (4.67) 0.00 
fruit & veg 15.11 (3.61) 13.70 (4.07) 0.01 
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Table 2. Screening and Neuropsychological Test performance according to AAN classification 
  HAND Category   
  Normal (n=18) ANI (n=13) MND (n=30) HIV-D (n=35) Kruskal Wallis p-value 
IHDS total 11.11 (1.08) 10.92 (0.76) 10.23 (1.17) 9.69 (1.97) 0.01 
IHDS FT subscore 3.50 (0.68) 3.78 (0.44) 3.78 (0.52) 3.25 (1.00) 0.10 
IHDS hand sequence subscore 3.83 (0.39) 3.55 (0.73) 3.09 (0.77) 2.96 (1.10) 0.02 
IHDS 4-word recall 3.92 (0.29) 3.55 (0.73) 3.30 (0.87) 3.09 (1.07) 0.03 
FT non-dom 7.54 (1.34) 8.68 (1.62) 8.93 (1.98) 9.59 (2.34) 0.01 
GP non-dom 77.80 (10.09) 88.49 (9.15) 78.35 (11.06) 99.07 (37.28) 0.00 
HVLT recall 8.17 (1.38) 7.06 (1.80) 7.40 (1.95) 6.11 (2.30) 0.01 
BVMT recall 8.72 (2.11) 7.31 (3.15) 7.37 (3.22) 4.37 (3.38) 0.00 
MAT 18.56 (6.16) 16.92 (4.44) 17.50 (5.35) 14.79 (4.24) 0.06 
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Mental control 22.22 (5.39) 21.23 (4.49) 20.57 (5.76) 16.41 (4.74) 0.00 
Digit symbol 51.06 (18.03) 50.83 (9.58) 52.91 (17.06) 32.46 (9.44) 0.00 
TMTA 46.96 (11.0) 52.34 (14.55) 58.73 (21.20) 77.29 (44.47) 0.00 
CT1 39.40 (10.11) 49.40 (15.92) 53.51 (14.63) 61.72 (17.30) 0.00 
CT2 101.17 (24.85) 115.96 (36.28) 105.79 (32.87) 150.39 (60.21) 0.00 
Stroop C/W 31.24 (9.46) 30.17 (7.87) 29.86 (8.54) 23.59 (8.94) 0.00 
WCST per errors 28.47 (12.10) 41.15 (11.58) 43.57 (23.61) 56.94 (30.24) 0.01 
Category fluency: animal 16.17 (4.11) 12.77 (4.11) 13.40 (4.70) 11.86 (4.60) 0.03 
Category fluency: fruit & veg 16.17 (4.09) 13.31 (3.84) 14.60 (3.49) 11.80 (3.81) 0.00 
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Table 3. Correlation coefficients of the IHDS total, finger-tapping, hand-sequence and recall subtests with the battery of neuropsychological 
tests with p-values 
  IHDS total IHDS FT  IHDS Luria IHDS  recall 
FT non-dom  0.26 (0.01)* 0.26 (0.03)* 0.26 (0.03)* 0.17 (0.15) 
GP non-dom -0.03 (0.78) -0.01 (0.97) -0.06 (0.60) -0.06 (0.59)  
HVLT recall 0.29 (0.00)* 0.30 (0.01)* 0.12 (0.31) 0.30 (0.01)* 
BVMT recall 0.35 (0.00)* 0.18 (0.12) 0.35 (0.00)* 0.27 (0.02)* 
MAT 0.09 (0.43) 0.09 (0.45) 0.10 (0.42) 0.11 (0.36) 
Mental control 0.22 (0.03)* 0.33 (0.00)* 0.12 (0.31) 0.18 (0.14) 
Digit symbol 0.19 (0.06) 0.14(0.24) 0.15 (0.20) 0.14 (0.23) 
TMTA 0.03 (0.78) 0.07 (0.58) -0.03 (0.83) -0.05 (0.66) 
CT1 0.35 (0.00)* 0.24 (0.04)* 0.37 (0.00)* 0.36 (0.00)* 
CT2 0.21 (0.04)* 0.34 (0.00)* 0.03 (0.78) 0.27 (0.02)* 
Stroop C/W 0.10 (0.38) 0.23 (0.06) 0.09 (0.48) -0.11 (0.35) 
WCST per errors 0.19 (0.06) 0.10 (0.27) 0.08 (0.53) 0.11 (0.36) 
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Category fluency: animal 0.13 (0.22) 0.19 (0.00)* 0.06 (0.61) 0.09 (0.46) 
Category fluency: fruit & veg 0.26 (0.01)* 0.18 (0.00)* 0.23 (0.05) 0.22 (0.06) 
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Figure 1. ROC Curve of Total IHDS compared to HAND categories as gold standard (AAN disorder categories vs asymptomatic groups) 
 
(SE=0.051; 95% confidence interval  0.607- 0.808) 
Using a cut-off score of 10 or less, the sensitivity of the IHDS was 81% and the specificity was 54%.  




   
Table 4. Cut-off points of the IHDS against the HAND classification 
      
Cutpoint Sensitivity Specificity Classified 
(≤ 4) 1% 100% 33% 
(≤6) 3% 100% 34% 
(≤7) 9% 100% 38% 
(≤8) 16% 96% 42% 
(≤9) 33% 93% 53% 
(≤10) 53% 80% 62% 
(≤11) 86% 32% 68% 
( ≤12) 100% 0% 67% 
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The impact of highly active anti-retroviral therapy (HAART) on individuals initiating 
therapy in South Africa where clade C HIV is predominant is unknown. In this study 
we sought to describe the change in neuropsychological function in a cohort of 
participants initiating HAART over a one year period. Participants included a group 
of individuals commencing HAART (n=82) and a group who did not (n=22). Baseline 
and one-year neuropsychological function was assessed using a detailed 
neuropsychological battery. Between-group comparisons, as well as unadjusted and 
adjusted linear associations were evaluated. A total of 105 participants were 
assessed at two time points a year apart. Retained participants had a median CD4 
cell count of 165 at baseline and 350 at follow-up. There was no difference in 
baseline or follow-up summary neuropsychological score between the HAART -
initiating and non-initiating groups (p=0.54 and p=0.17 respectively). There was a 
trend for the group initiating HAART to show a greater degree of neuropsychological 
change (p=0.08). There was an association between worse baseline 
neuropsychological score and greater neuropsychological change for both groups 
(p<0.01). This association remained significant in a model that adjusted for baseline 
CD4 cell count and HAART use as additional independent variables (p=0.03). All 
included participants improved over one year, although individuals initiating HAART 
showed a trend to greater neuropsychological improvement than those not initiating. 
The most impaired individuals seemed to benefit most. Studies with larger 
comparison groups, and where HIV disease characteristics are needed to establish 
whether the trends we identified are clinically meaningful. 





In this chapter, I describe the impact of HAART on neuropsychological function at 
one year in the cohort. As I have outlined previously, it is not known whether HAART 
exerts the same effects in individuals infected with clade C HIV; whether particular 
domains benefit more than others; and whether there are certain predictors or 
associated variables of change. People living with HIV in South Africa frequently 
commence HAART at a late disease stage; it is therefore important to document the 
extent to which HAART can reverse pre-treatment impairment. This would allow for 
planning of treatment support, tailoring of treatment regimens or providing adjuvant 
therapies, and motivating for earlier treatment initiation in cases where significant 
impairment exists at higher CD4 cell counts. Neuropsychological impairments due to 
HIV infection of the CNS are detectable across all disease stages, but are more 
prevalent and marked in individuals with more severe HIV disease [1,2]. Although the 
use of HAART has halved the incidence of HIV-associated dementia (HAD), the 
prevalence remains significant [3].  
Several published studies have reported on neuropsychological improvement 
following HAART initiation [4-6]. To date, this improvement has been ascribed to 
effective peripheral viral load suppression, CNS penetration effectiveness (CPE) of 
HAART regimens, and has been associated with severity of baseline (or study entry) 
neuropsychological function, and possibly also practice effects in cohort studies [6-9].  
More recently attention has also been drawn to the potential for highly penetrating 
HAART regimens to exert neurotoxic effects. In one recent study, individuals with low 
CSF viral loads and high CPE ranked regimens had more impaired 
neuropsychological function than individuals with higher CSF viral loads [10]; and in 
another cohort study, immunologically reconstituted individuals who interrupted 
CART performed better over a two year period than those who continued treatment 
[9].  
The impact of HAART in a prospective study in South Africa where clade C HIV is 
predominant has not been reported. In this study, we hypothesized that individuals 
initiating HAART would show improved neuropsychological function over one year. 
Moreover, we hypothesized that individuals with more severe disease at baseline 
would have worse neuropsychological outcomes at one year.   
 






This study was conducted as part of a larger investigation of HIV-associated 
neurocognitive disorders (HAND) in Cape Town, South Africa previously described 
[11]. In summary, we conducted detailed neuropsychological assessments on 165 
participants recruited from three primary health care centres. At each visit, detailed 
socio-demographic and neuromedical measures were also administered and 
laboratory tests completed. Included individuals ranged from 18 through 40 years, 
and were assessed prior to commencing treatment with HAART. They were excluded 
if they had a severe psychiatric disorder (such as schizophrenia or bipolar disorder), 
recent (within the last three months) history of substance abuse, or significant 
neurological disorder (such as epilepsy or significant head injury defined as a loss of 
consciousness for more than 30mins). We were able to retain 105 participants at one 
year study follow-up assessment. Of this group, 22  were deemed not to have 
initiated HAART - one participant had one month of treatment before being 
imprisoned and defaulting. Of the remaining 21, 15 had CD4 cell counts above the 
guideline for initiation and were not enrolled onto HAART. Their CD4 cell counts were 
unknown at the time of initial study recruitment. The other six participants qualified for 
HAART, and were included in the study on an intention to treat basis, but had not 
attended clinic appointments during the one-year period and so were not initiated. 
Neuropsychological technicians were blinded to the use of HAART at one year 
assessment.  
 
Normative data for neuropsychological testing was obtained from 94 HIV- negative 
participants. These participants were recruited from Voluntary Counseling and 
Testing services at the same primary care clinics. We liaised with lay counsellors 
conducting testing at the clinics to obtain lists of potential participants who had been 
both counselled and tested. We approached potential participants drawn from these 
lists. Other than being HIV negative, as confirmed by a recent rapid HIV test and 
confirmatory serological test, inclusion and exclusion criteria were identical to the 
HIV-positive participants.  
 
The CD4 cell count and viral load were extracted from the laboratory records, linked 
by the participants’ clinic numbers. Clade sequencing was not available on this 
sample but 89% of infected individuals in the Cape Town area are infected with clade 
C virus [12]. Hepatitis sero-status was not established but the prevalence of hepatitis 
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C in South Africa is extremely low [13]. The use of HAART was also extracted post-
hoc from clinical records, and the CPE rank for each was calculated using previously 
published criteria [7]. 
 
All participants who met study criteria and agreed to participate provided written 
informed consent. Approval to conduct the study was obtained from the Research 
Ethics Committee of the Faculty of Health Sciences, University of Cape Town, and 
from the relevant health authorities.  
 
Neuropsychological test battery 
A neuropsychological test battery was administered to all participants to assess 
specific domains of neurocognitive function. The battery comprised tests of the 
domains: attention (the Mental Alternation Test (MAT) and the Mental Control Test 
(MCT)), learning and memory (the Hopkins Verbal Learning Test (HVLT) and the 
Brief Visuospatial Memory Test (BVMT)), psychomotor speed (Finger tapping (FT) 
and the Grooved Pegboard Test (GP)), psychomotor speed (Trail Making Test part A 
(TMTA), Color Trails Test 1(CT1) and Digit Symbol-Coding (DSC)), executive 
function (Color Trails Test 2 (CT2), Stroop Colour-Word test (SCW), Wisconsin Card-
Sorting Test (WCST), and language (category fluency)).  
 
Determination of global neuropsychological function 
We used the above neuropsychological test battery to generate global 
neuropsychological performance scores for each participant. For each 
neuropsychological test, we generated a z-score by using the formula: (raw score-
control mean)/control standard deviation. We then summed the z-scores for each 
participant and divided by the number of tests included to arrive at a global 
neuropsychological score.  
 
Statistical analysis 
Data were analysed using STATA 11 (Stata Corporation, Texas, USA). As data were 
not normally distributed across all variables, we calculated medians and interquartile 
ratios for the one- and two-visit groups, as well as the HAART and non-HAART 
groups. Comparisons were made using Wilcoxon rank sum tests or Fisher Exact 
tests where appropriate. We generated box-and-whisker plots for the two time-points 
of the HAART and non-HAART groups, and compared mean summary scores using 
paired t-tests. We then evaluated linear trends first using simple models across all 
retained participants, HAART-initiators and non-initiators, with change in summary 
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score between follow-up and baseline as the dependent variable. We included 
independent variables in a final multiple linear regression, if the simple model 
rendered a p-value of less than 0.1, or the variable was known to be strongly 
associated with neuropsychological test performance. The final model included 




Of the total recruited cohort, 109 participants were retained and completed 
neuropsychological (NP) batteries at the two time points, while 56 were not retained. 
Of these 56 participants, nine had deceased before the follow-up period, six had 
migrated out of the district, 33 were lost to follow-up (had not attended routine clinic 
for at least 3 visits and could not be tracked after three telephone calls), and the 
remaining eight were not retained for unknown reasons.  
 
Demographic, disease and neuropsychological characteristics of the retained and 
non-retained groups are presented in table 1. The retained participants performed 
better than those not retained on their baseline neuropsychological summary score 
(p=0.02), as well as on a number of individual neuropsychological tests, including GP 
non-dominant (p=0.02), HVLT recall (p=0.04), BVMT recall (p=0.02), TMTA (p=0.01) 
and category fluency (fruit and vegetables) (p=0.01). Retained participants were seen 
again after a mean of 12.9 months (SD 3.13), while their CD4 cell count had 
improved from a median of 176 (IQR 121-221) to 330 (IQR 241-464).  
 
Of the 109 participants who were retained, full data were available for 104. Of these, 
82 had initiated HAART (mean duration of use 11. 6, SD=6.04), and 22 had not. 
When these two groups were compared, the HAART group had a significantly lower 
CD4 cell count at baseline (medians 183 vs 195; p<0.01) and had a longer period 
since being diagnosed with HIV (medians 3 years vs 1 year; p=0.01). Of note, there 
was no significant difference between HAART -initiators and non-initiators with 
respect to baseline summary NP scores (medians -0.42 vs -0.58; p=0.54), but they 
did differ with regard to CT1, SCW and category fluency (animals). There was again 
no significant difference at one-year follow-up when participants on HAART were 
compared to those not, regarding summary NP score (medians -0.12 and -0.39; 
p=0.17); however there was a trend for those using HAART to have shown a greater 
degree of improvement (median NP change 0.28 vs 0.13; p=0.08). The majority of 
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the participants (n=73) initiating HAART group had a CNS penetration effectiveness 
rank of 1.5 or more.  
 
When we compared the global neuropsychological test performance of the two 
groups at baseline and follow-up, we note that both had improved significantly 
(means from -0.42 to -0.13 for the HAART group, p<0.01; and means -0.51 to -0.36 
for the non-HAART group p= 0.04). The box and whisker plots of their global 
neuropsychological test performance are shown in Figure 1.  
 
The unadjusted linear associations between a number of independent variables and 
change in global NP performance were then examined for all retained participants, 
those initiating HAART, and those not initiating (Table 3).  The independent variables 
considered were HAART use, age, gender, level of education, years since diagnosis, 
baseline CD4 cell count, baseline NP summary score, months between testing, CPE 
rank and viral load at follow-up. There was a negative association between baseline 
NP summary score in the unadjusted associations for the whole participant and 
HAART-initiating groups (p<0.001 CI -0.27 to -0.08; p<0.001 CI -0.31 to 0.10). In 
those initiating HAART, male gender was associated with greater change in NP 
score (p=0.01, CI 0.04 to 0.35).  
 
In the adjusted model for all participants, we included baseline CD4 count, baseline 
NP summary scores and HAART use as predictors. The overall model was 
significant (p<0.00), with only baseline NP score remaining significantly predictive of 
NP change (p<0.00). The use of CART was not significant in this model (p=0.21). In 
a separate model including only participants initiating HAART, the overall model was 
significant (p=0.003), with baseline NP score again significant (p=0.04),as well as 




We report on the first follow-up study conducted among a dominant clade C group of 
patients utilizing a detailed neuropsychological battery to establish the effects of 
HAART. The majority of participants (66%) was retained and completed the study 
one-year later. Of these, 74% (n=82) had commenced HAART, while 26% (n=22) 
had not, allowing us to compare outcomes with a group exhibiting similar disease 
characteristics. While both initiators and non-initiators improved significantly on 
global NP summary score, there was a trend for the HAART -initiating group to show 
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a greater degree of NP change at one year. Using unadjusted and adjusted linear 
models, we found that the degree of baseline neuropsychological performance was 
most strongly associated with neuropsychological change. A trend was noted 
between use of HAART and neuropsychological improvement in the unadjusted 
model. 
The use of HAART has frequently been reported as improving neuropsychological 
outcomes in prospective cohorts [3,6,14,15]. However, few studies have been able to 
include a control group with similar demographic and disease characteristics. This 
has been pointed out to be an important need in the literature [9]. Our control group 
had significantly higher baseline CD4 cell count (medians 172 and 329 respectively; 
p<0.01). While both groups represent substantial immunocompromise, it is not 
possible to draw clear conclusions. It is not possible to obtain a fully matched 
untreated control group. Both HAART initiating and non-initiating groups improved 
significantly over one year (p<0.01 and p=0.02 respectively). Several possible 
explanations for neuropsychological change over time exist, including real change (in 
this case due to HAART), baseline performance, participant variables (such as age, 
neuropsychological “competence”), test profile, time between testing, and mental 
state at the time of testing. The issue of practice effect has frequently been raised as 
a confound to measuring real change in neuropsychological test performance over 
time. Strategies to deal with re-testing include statistical prediction of follow-up 
testing and comparing this to performance to see whether real change has occurred. 
A number of possible contributors to change may then be included in the model to 
control for these confounds. The strongest predictor of follow-up performance is 
baseline performance: worse performance at baseline predicts worse performance at 
follow-up. Other factors such as older age and lower education also predict poorer 
repeat performance [16]. We found the opposite effect with regard to baseline 
performance. For this reason, and the absence of a “norming” dataset, we did not 
perform predictive scoring to control for repeat testing. Also, it can be argued that the 
one year interval between testng is sufficiently long to reduce practice effects. It is 
possible, however, that the previous experience of being tested does improve 
“neuropsychological competency”- a factor recognised in the literature to improve 
performance [16].  
Neuropsychological improvement was significantly associated with a greater degree 
of baseline neuropsychological impairment, in unadjusted models including all 
retained participants, as well as HAART -initiators (p<0.01 and p<0.01 respectively). 
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This association remained significant in a final adjusted linear model, which included 
baseline CD4 count and HAART use as independent variables (overall significance 
(p=0.01). This finding is not surprising, given that HAART is known to reduce the 
incidence but not the prevalence of severe forms of HAND [3]; and that HAART has 
been reported to exert a limited impact on individuals with less severe impairment, or 
who were on stable regimens [17]. In addition, our participants had late stage 
disease by virtue of their low CD4 cell counts. This finding stands in contrast to the 
neuropsychology literature, which asserts that worse baseline performance predicts 
worse repeat performance [16]. This lends support to the conclusion that the 
improvement seen was real change. When we included HAART use in an unadjusted 
linear model, we a trend association with neuropsychological improvement (p=0.07).  
This effect become non-significant in the final adjusted model, most likely due to the 
relatively small non-HAART comparison group and the strong effect of severity of 
baseline NP impairment. The improvement of both groups of participants may also 
be ascribed to a “neuropsychological competency effect”.    
We did not detect an effect of different CPE ranks, as first-line regimens, used by the 
majority of participants in our study have high CPE ranks (73 of 82 participants had a 
CPE rank ≥1.5). Also, almost all participants achieved peripheral viral load 
suppression during the first year of treatment, and therefore were adequately 
immune reconstituted. This suggests that they were also adherent to treatment.  
There were a number of limitations to our study. First, a significant number of 
participants were not retained, despite our best efforts at retention. These individuals 
performed significantly worse on neuropsychological summary score (p=0.02). Also, 
the sample size of the non-initiating group was restricted, and this could have 
impacted on our findings. Although the two comparison groups differed with respect 
to CD4 cell count, this was the result of anti-retroviral guidelines in South Africa, as 
those with CD4 cell counts >200 cells/ml do not qualify for HAART. We were not able 
to obtain CSF in order to characterize intra-thecal viral load or inflammatory markers, 
again for ethical reasons.  
We believe that this study makes an important contribution to our understanding of 
the effect of HAART on neuropsychologically impaired individuals. It highlights the 
fact that individuals initiating HAART in South Africa, were clade C HIV is highly 
prevalent, may benefit neuropsychologically. This benefit seemed to accrue most to 
individuals with more severe baseline impairment. Studies with larger comparison 
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groups, and where HIV disease characteristics are similar, are needed to establish 
whether the trends we identified are clinically meaningful or specific to HAART itself. 
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Not retained          
(n= 56) p-value 
Age: median (IQR) 29.55 (27-32) 29.54 (27-32) 0.63 
Level of education: median (IQR) 10 (9-12) 10 (8-11) 0.35 
Home language isiXhosa: n (%) 99 (91) 47 (84) 0.05 
Baseline CD4: median (IQR) 182 (136-240)  165 (88-224.5) 0.47 
Years since diagnosis: mean (SD) 3.29 (2.43)    
Months between visits: mean (SD) 12.93 (3.13)    
Follow-up CD4 330 (241-464)    
Follow-up viral load 1.69      
Baseline neuropsychological z-scores: median (IQR)      
Summary score -0.51 (-0.9- 0.3) -0.62 (-1.26- -0.12 ) 0.02* 
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FT non-dom -0.7 (-1.63- -0.12) -1.1 (-2.11- -0.46) 0.08 
GP non-dom -0.18 (-1.2- -0.62) -0.53 (-1.43- 0.19) 0.02* 
HVLT recall -0.04 (-1- 0.45) -0.52 (-1.49- -0.04) 0.04* 
BVMT recall -0.33 (-1.7- 0.35) -1.01 (-2.38- 0.01) 0.02* 
MAT -0.07 (-0.37- 0.53) -0.07 (-0.52- 0.23) 0.44 
Mental control -0.62 (-1.29- -0.11) -0.96 (-1.63- -0.28) 0.09 
Digit symbol -0.47 (-0.98- 0.29) -0.54 (-1.01- 0.01) 0.19 
TMTA -0.59 (-1.49- -0.12) -1.09 (-2.38- -0.44) 0.01* 
Colour I 0.365 (-0.2- 0.78) 0.06 (-0.5- 0.59) 0.05 
Colour II -0.08 (-0.43- 0.45) 0.2 (-0.7- 0.42) 0.69 
Stroop C/W -0.65 (-1.32- 0.04) -0.59 (-1.32- -0.07) 0.89 
WCST per errors -0.19 (-1.32- 0.35) -0.46 (-1.02- 0.2) 0.39 
animal -0.39 (-1.25- 0.26) -0.6 (-1.47- 0.26) 0.25 
fruit & veg -0.03 (-0.86- 0.52) -0,58 (-1.42- 0.25) 0.01* 
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Not initiating HAART 
(n=22) p-value 
Age: median (IQR) 30 (27-32) 30 (28-34) 0.12 
Level of education 10 (9-12) 10.5 (9-11) 0.95 
Home language isiXhosa: n (%) 80 (97.5) 20 (91) 0.84 
Baseline CD4: median (IQR) 172 (121-214) 329 (321-602) <0.00 
Baseline neuropsycholgical z-scores: median (IQR)      
Summary score -0.42 (-0.9- 0.03) -0.58 (-0.93- -0.39) 0.54 
FT non-dom -.066 (-1.64- -0.12) -0.9 (-1.65- 0.11) 0.7 
GP non-dom -0.27 (-1.26- 0.67) 0.02 (-1.05- 0.56) 0.85 
HVLT recall -0.04 (-1- 0.45) -0.52 (-1- -0.04) 0.46 
BVMT recall -0.33 (-1.36- 0.35) -1.01 (-1.7- 0.35) 0.36 
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MAT -0.7 (-0.37- 0.53) -0.7 (-0.37- 0.53) 0.94 
Mental control -0.79 (-1.46- 0.22) -0.54 (-1.29- -0.11) 0.82 
Digit symbol -0.33 (-1.01- 0.42) -0.74 (-0.95- 0.33) 0.26 
TMTA -0.53 (-1.38- -0.02) -1.07 (-2.13- -0.27) 0.05 
Colour I 0.44 (-0.04- 0.8) 0.01 (-0.49- 0.36) 0.02* 
Colour II -0.1 (-0.52- 0.45) -0.18 (-0.4- 0.4) 0.85 
Stroop C/W -0.49 (-1.32- 0.14) -1.06- -1.43) 0.03* 
WCST per errors -0.11 (-1.58- 0.35) -0.39 (-1.07- 0.35) 0.92 
animal -0.6 (-1.25- 0.04) -0.07 (-0.6- 0.69) 0.04* 
fruit & veg -0.03 (-0.86- 0.8) -0.31 (-1.14- -0.03) 0.05 
Years since diagnosis: median (IQR) 3 (2-5) 1 (1-2) 0.00* 
Months between visits: median (IQR) 12 (11-14) 12 (11-15) 0.68 
Follow-up CD4: median (IQR) 324 (231-451.5) 430 (241-560) 0.35 
Follow-up viral load: median  1.69    
Follow-up neuropsychological z-scores: median (IQR)      
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Summary score -0.12 (-0.56- 0.22) -0.39 (-0.75- 0.17) 0.17 
Neuropsychological change 0.28 (0.04- 0.51) 0.13 (-0.12- 0.39) 0.08 
FT non-dom -0.18 (-0.73- 0.28) -0.18 (-1.11- 0.32) 0.89 
GP non-dom 0.21 (-0.79- 0.66) 0.45 (-0.04- 0.93) 0.18 
HVLT recall -0.04 (-0.52- 0.93) -0.86- -2.02- 0.56) 0.30 
BVMT recall -0.67 (-1.7- 0.35) -1.36 (-2.38- 0.01) 0.06 
MAT -0.7 (-0.52- 0.53) 0.23 (-0.52- 0.82) 0.52 
Mental control -0.45 (-1.13- 0.73) -0.20 (-1.13- 0.39) 0.88 
Digit symbol -0.33 (-0.95- 0.49) -0.78 (-1.29- 0.35) 0.37 
TMTA -0.18 (-1.01- 0.31) -0.65 (-1.92- -0.39) 0.01* 
Colour I 0.47 (-0.13- 0.9) 0.49 (-1.1- 0.68) 0.38 
Colour II 0.28 (-0.27- 0.54) -0.27 (-0.86- 0.64) 0.29 
Stroop C/W -0.44 (-1.32- 0.32) -0.8 (-1.11- -0.38) 0.27 
WCST per errors -0.1 (-0.46- 0.56) -0.21 (-0.87- 0.35) 0.06 
animal 0.26 (-0.6- -.69) -0.17 (-0.82- 0.69) 0.42 
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fruit & veg -0.03 (-0.58- 0.8) -0.31 (-0.86- 0.8) 0.23 
Duration of HAART in months: mean (SD) 11.56 (10-12)    
CPE rank:                1 7    
1.5 - 2 47    
>2 26    
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Figure 1. Global neuropsychological performance of participants initiating HAART (left) (n=82) and not initiating HAART (right) (n=22) 
 
 
HAART group: p=0.000; non-HAART group: p= 0.02




Table 3. Unadjusted regression models for predictors of change in global neuropsychological test performance  
 All participants (n=105) HAART initiated (n=85) HAART not initiated (n=22) 
 Regression 
coefficient 






95% CI p-value 
HAART  -0.13 -0.28- 0.01 0.07       
Age  -0.01 -0.02- 0.01 0.45 -0.01 -0.03- 0.01 0.41 0.01 -0.04- 0.05 0.75 
Male gender 0.09 -0.05- 0.22 0.22 0.19 0.04- 0.35 0.01* -0.13 -0.46- 0.20 0.41 
Education -0.02 -0.05- 0.02 0.37 -0.03 -0.07- 0.01 0.11 0.05 -0.12- 0.03 0.15 
Years since diagnosis 0.01 -0.02- 0.04 0.67 -0.00 -0.03- 0.03 0.98 0.26 -0.37- 0.89 0.34 
Baseline CD4  -0.00 -0.00- 0.00 0.04* -0.00 -0.00- 0.00 0.03* -0.00 -0.00- 0.00 0.83 
Baseline Global NP -0.18 -0.27- -0.08 0.00* -0.20 -0.31- 0.10 0.00* -0.03 -0.33- 0.27 0.84 
Months between testing -0.00 -0.02- 0.02 0.79 -0.00 -0.03- 0.02 0.75 0.03 -0.02- 0.07 0.20 
CPE    0.00 -0.14- 0.14 0.95    
Viral load at follow-up 0.04 -.016- 0.13 0.46       
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Chapter 8.  
 
Summary and Conclusions 




As summarized in earlier chapters, the need for further investigation into HIV-
associated neurocognitive disorders (HAND) in South Africa is underscored by five  
key problems: (1) that HIV infection is epidemic in southern Africa, with the highest 
number of infected people in the world living in South Africa, and that there may be 
key differences in the epidemic in this region as opposed to othes [1]; (2) that HIV 
infects the brain early in infection, exerts neurotoxic effects throughout the long 
asymptomatic phase of the illness, and that these effects are most pronounced with 
more severe immune-compromise [2,3]; (3) that adverse neurotoxicity of HIV 
manifests commonly as neuropsychological impairments across a number of 
neurocognitive domains [4]; (4) that HAND have a dramatic effect on a range of 
behavioural and health outcomes, such as employment status and function, impaired 
activities of daily living such as driving, and poor medication adherence (with 
consequent viral resistance and adverse health outcomes) [5]; and (5) that despite 
the impact that highly active anti-retroviral therapy (HAART) has had on reducing 
severe forms of HAND, mild forms remain prevalent [6]. Indeed these milder forms 
may also exert deleterious effects on functional abilities.  
 
Despite the fact that HIV is most prevalent in Southern Africa, most of the empiric 
research has been conducted in North America and to a lesser extent in Europe. The 
epidemic in these high-income countries (HICs) differs from that in South Africa- a 
middle-income country (MIC)- in several important psycho-social and biological ways: 
(1) spread- in HICs, HIV transmission is primarily driven by intra-venous drug abuse 
and by homosexual contact, while in MICs, spread has been driven by heterosexual 
contact, and indeed by the phenomenon of sexual concurrency [1]; (2) Size and 
resources- the size of the epidemic and the availability of resources in MICs is not 
only vastly different, but has an effect on prevention and treatment of HIV-related 
disorders; (3) Poverty and socio-demographic factors- people infected with HIV in 
MICs are more likely to be poor, have lower levels of education, and have a higher 
burden of co-morbid physical disease, than those in HICs [1]; (4) HIV-1 sub-type- the 
HI virus frequently mutates and recombines to form different variants. Of the main 
group of HIV-1 sub-types or clades, sub-types A, B, C and D are commonest, but 
they are not equally distributed across the globe. HICs have a predominance of sub-
type B, while Southern Africa has a predominance of sub-type C [7]. Genetic 
differences in HIV-1 clades may be relevant in two ways- first, that there may be 
putative differences in neurotoxicity of the different clades; second, that people 
infected with different clades of HIV may respond to HAART differently [8].  




In vitro work has suggested that the clade C viral tat protein exerts a lesser 
neurotoxic effect than that of clade B tat protein [8]. In the first locally published 
clinical study, using a brief cognitive screening tool, which in large part challenged 
this hypothesis came from our Cape Town group [9] - the second, which provided 
detailed characterisation of neurocognitive disorders, is part of this thesis (see 
chapter 4). Further studies which investigate the association between 
neuropsychological impairments and the genetic make-up of the HIV-1 sub-type 
producing HAND in individuals in Cape Town are needed. The second important 
aspect of understanding HAND in our population- that of response to HAART- was 
also addressed by this thesis. We have been able to show that individuals with 
severe HAND benefitted significantly over the course of one year of treatment, 
although it is likely that neuropsychological performance is likely to be affected by 
practice effects or “test experience familiarity”. 
 
In chapter 5, we were able to demonstrate that apolipoprotein E4 (APOE4) is a more 
common variant in Cape Town than other regions [14], but that it was (a) not over-
represented in individuals with HIV-associated dementia, and (b) that the APOE2 
variant appeared to be under-represented in the HIV-positive cohort. Further work to 
explain these findings by including an adult HIV negative control group is needed. In 
addition to APOE, other gene candidates and protein products which predispose to 
the development of HAND have been proposed, including monocyte-chemoattractant 
protein-1 (MCP-1) [10,11]. The theoretical basis of APOE lies in its association with 
the development of a range of neurocognitive disorders, such as dementia following 
traumatic brain injury and Alzheimer’s disease. In these conditions, the APOE4 
variant occurs more frequently in people with dementia, probably as the result of 
defective lipid metabolism and consequent vasculopathy [12]. A few studies linking 
APOE4 to adverse outcomes in HIV have been done, though with diverse 
results[11,13]. Longer prospective studies are needed to identify the role that 
APOE4, HAART use and ageing may have on neurocognitive outcomes. All are 
associated with an increased in vascular risk factors. 
 
Further acquired and socio-demographic factors may impact on the development of 
HAND. These include intellectual disability, low level and quality of education, 
gender, the presence of substance abuse, co-morbid infections (such as hepatitis C), 
history of traumatic brain injury and advancing age [6,15]. In this thesis screened 
individuals in order to control for their effects. Other factors, such as nutritional 
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status, we reported on in chapter 4. These were not associated with the development 
of HAND.  
 
Viral factors, and host-viral interactions are also part of a model of 
neurodegeneration, though poorly understood. Clues to these mechanisms must be 
sought across different modalities of study, and synthesised into a coherent model. 
These include clinical studies, imaging studies, investigation into neuro-inflammation, 
and as mentioned above, correlations between viral genotype and 
neuropsychological outcomes. More recent studies have begun to focus on early HIV 
infection and the sequence of ensuing lympho- and neuro-invasion [16]. These 
suggest that much of what occurs later in HIV disease is determined by early host-
viral factors.  
 
Summary of findings 
It is now well-established that HAND are both common and disabling. In developed 
countries, rates of HAND (including milder forms) has been estimated to be between 
30-60%. In the face of questions being raised in the literature concerning possible 
differences between the neurotoxicity of the different HIV clades, it has become 
important to document the extent to which HIV causes neuropsychological 
impairment in South Africans. In this work, the first to utilise a detailed 
neuropsychological test battery in adults attending HIV clinics in South Africa, we 
were able to show that HAND are common in the Western Cape of South Africa- with 
a prevalence of HIV-associated dementia (HAD) of 25.4% of individuals entering 
care. Nearly two-thirds of all individuals assessed had some form of neurocognitive 
disorder. These patients tended to be older and less well educated, with a trend to 
lower CD4 cell counts. When we examined anthropomorphical and nutritional and 
measures, these were found to bear no associated with the development of HAND. 
The relevance of these findings is not only to confirm that clade C is indeed 
neurotoxic and produces high rates of HAND, but to underline the importance of 
understanding mechanisms of disease, improve detection, and therefore to improve 
treatment outcomes. 
 
In a genetic analysis, as discussed above, we investigated the putative role that 
APOE might play in the development of HAD. We found that the E4 variant was not 
associated with HAD in our sample. While other investigators have raised the 
possibility that individuals with the E4 variant may not survive into older age [15], our 
participants were younger, and therefore we could not explore this hypothesis. In the 
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absence of a group of adult controls, we are also unable to draw clear conclusions 
about the lower allelic frequency of the E2 allele in the HIV positive participants. An 
hypothesis which requires further exploration is that the E2 variant may be protective 
against HIV infection.  
 
With the high prevalence of HAND noted, we proceeded in chapter 6 to establish 
whether or not the International HIV Dementia Scale (IHDS) would be a useful 
screening tool in our setting. It has previously been validated in Uganda, with some 
preliminary work being published from Botswana. We found that when we combined 
individuals with HIV-associated dementia and those with mild neurocognitive 
disorder, the IHDS performed satisfactorily, using a cut-off score of ≤10 on the scale. 
However, the sensitivity was much improved when we raised this to ≤11, although 
the specificity was low. Clinicians may need to consider using this higher cut-off in 
our setting. It is not clear whether differences in neuropsychological effects of HIV 
across different countries might account for this. 
 
In chapter 7, we reported significant improvements in neuropsychological 
performance in both groups (HAART initiators and non-initiators), with the effect of 
HAART offering a trend to significance in an unadjusted linear model. This is likely 
explained by a range of testing variables, not least the “test experience familiarity” 
mentioned above. The group initiating HAART showed a trend towards a greater 
degree of neuropsychological improvement, as reflected in a summary change score. 
A greater degree of baseline neuropsychological impairment was predictive of 
improvement at one year in unadjusted and adjusted models of neuropsychological 
improvement. Studies of the effect of HAART on neuropsychological outcomes are 
limited by a range of factors. First, studies differ in the extent of the batteries 
employed, with some using as few as three or four test measures. Second, cohorts 
across studies differ with respect to disease characteristics- many such studies have 
reported on individuals already on HAART, as opposed to pre- and post-treatment. 
Thirdly, with repeated measurements being conducted, there is the problem of 
practice effects in testing. These are clearly exacerbated with shorter periods 
between tests, even when different forms are used. Our view is that even using a 
one-year test-retest interval, participants who are not well-educated are more familiar 
with the experience of being tested. In attempting to control for this practice effect, 
and to establish the effect of HAART, a control group of untreated individuals would 
be best. In our study, we were able to include a small sub-sample of individuals not 
treated, but who completed 2 assessments over one year.  





We have been able to confirm using a detailed neuropsychological test battery, and 
medical and functional assessment, that HIV-associated neurocognitive disorders are 
highly prevalent in young adults commencing HAART in the Western Cape. This 
confirms the single earlier report from Cape Town, using only a brief cognitive 
screening tool, that HAND are indeed prevalent in individuals infected with clade C 
HIV. While this finding is in keeping with international studies, especially of 
individuals at this severe disease stage (that is, with CD4 cell counts <200 cells/ml), 
our high rates suggest that these patients might be developing HAND much earlier, 
and therefore should be screened. With the large number of individuals needing to 
initiate treatment, it is likely that clinicians are being guided mainly by CD4 cell 
counts, rather than clinical indications, unless a life-threatening illness presents itself. 
We would argue that with more active screening at higher CD4 cell counts, 
individuals may be referred for more formal testing, and if found to have a HAND, 
should be initiated onto HAART. Tools such as the IHDS may be used for this 
purpose, followed by focussed neuropsychological batteries. 
 
Individuals with severe neuropsychological impairment demonstrate an improvement 
in neuropsychological scores after HAART. Some of this effect may be due to 
practice effects. The presence of residual deficits (individuals initiating HAART had a 
summary neuropsychological deficit score of -0.12), suggests that either certain 
neurodegeneration is irreversible, or that further improvement could occur over a 
longer period of time. Implications include the possibility of adding adjuvant 
neuroprotective treatments, re-assessing patients over time, and the impact of 
impaired functional abilities for this duration.  
 
Limitations of this study 
This study has a number of limitations. First, we noted along with other investigators, 
that our measures of activities of daily living and functional ability were inadequate. 
This occurred for a number of reasons, including that many participants are 
unemployed, and therefore this aspect of life cannot be measured. Also, we propose 
that a significant amount of executive function needs to be lost in order to be 
measure by a “crude” self-report scale. Lastly, we hypothesise that many individuals 
under-report the extent of their functional deficits, either through shame or loss of 
insight. The need for a broad-based, culturally-appropriate and yet sensitive tool to 
measure functional ability is great.  




Another limitation was the lack of randomisation of participants into a non-HAART 
control group. The importance of this sub-group only become clear once the study 
had complete recruitment. A prospective, controlled study comparing similar disease 
groups of important key measures would add greatly to knowledge of the impact (or 
not) of HAART, and whether adjuvant treatments should be considered. As it would 
not be ethical to withhold treatment from participants who would normally qualify for 
treatment, it would be necessary to utilise a comparison group with similar disease 
characteristics, but who did not qualify for HAART under current guidelines. Such a 
group in South Africa may be constituted of participants with CD4 cell counts from 
200-350 cells/ml. In my study, though, we were able to identify only 22 treatment-free 
participants, which may have limited our ability to make draw firm conclusions about 
this group.  
 
We did not conduct clade sequencing of our participants at this time. This would have 
enabled to us to more definitively describe the relationship between the respective 
clade and viral genome, and the extent and nature of neuropsychological impairment. 
Previous studies of HIV clade in Cape Town have confirmed that the “C” sub-type is 
predominant [17].  
 
The further detailing of neuropathology of HAND through the use of magnetic 
resonance imaging (MRI) could have added a useful component to the study. While 
we were able to image a small sub-set of participants, these data were included in 
this clinical analysis. Larger samples of imaged participants are needed to better 
understand the association between neuropsychological performance and brain 
structure. Modalities such as diffusion tensor imaging may be useful in detailing white 
matter damage induced by HIV neurotoxicity [18]. In addition, careful viral 




A number of important clinical issues should be considered as a result of this 
research. These include the importance of screening for HAND in patients at HIV 
“wellness clinics”, monitoring neuropsychological progress of patients initiating 
HAART with a view to providing adjuvant treatments, and considering additional 
psycho-social support to patients with functional disability as a result of HAND. 
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As previously outlined, HAND are common, and may occur at CD4 cell counts above 
200 cells/ml. It is current practice in the Western Cape that this group of patients are 
seen 3-6 monthly by nurse practitioners. They are referred into pre-HAART 
counselling once their CD4 count falls to below 200 cells/ml, or they develop stage 3 
or 4 clinical conditions. It is our experience that these patients are not routinely 
screened for neurocognitive problems. Individuals who score ≤11 on the IHDS should 
be referred for further confirmatory assessment, and then a motivation for inclusion in 
to HAART provided. Further end-organ brain damage might be prevented if this 
practice were implemented. 
 
To date, there have been relatively few clinical trials of adjuvant treatments for 
persistent HAND in the context of HAART. These include agents currently registered 
in South Africa for other conditions- namely, memantine and lithium [19,20]. Brief 
trials of these agents have suggested benefit, but further work with our local 
population is needed before they can be used in routine clinical practice. 
Nonetheless, the need for a cost-effective, well-tolerated and clinically effective agent 
is pressing. 
 
The need for studies to address neuropsychological issues is also urgent. In this 
regard, our group has commenced a study of normative data in the Western Cape. 
Other related studies should include closer examination of the internal properties of a 
battery- that is, whether certain tests correlate more or less strongly with global 
effects. Also, concerted efforts to understand and develop both culture and language-
appropriate tests are needed. For example, can isi-Xhosa speakers understand blue-
green differences, as in the Stroop test. 
 
Finally, despite limited resources, clinic teams must consider strategies to support 
patients with HAND, especially if they are on HAART. This may take the form of more 
focussed family or treatment support partner counselling, regarding the needs for 
support; or lay counsellor/home-based carer interventions. Individuals who are 
employed may benefit from occupational therapy assessment, support or job 
description re-assignment. Further work is needed to translate the 
neuropsychological impact of HAND into occupational disability across a range of 
occupations in South Africa- not least mining, driving, or machine operation. 
 
Future research 
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A number of further studies should be considered following this work. First, larger 
prospective studies using comparison groups of participants with similar disease-
stage initiated and not initiated on HAART would allow for clearer delineation of the 
effects of HAART on neurocognitive outcomes. Second, such studies would also 
allow for understanding the correlations between neuropsychological impairment, 
viral genetics and neuro-imaging findings. This may provided clearer links between 
viral clade, specific neuropsychological impairments and brain regions affected. 
Third, prospective treatment studies should investigate the effects of CNS 
penetrating and non-penetrating regimens of HAART in order to describe not only the 
potential benefits of better-penetrating regimens, but also the potential neurotoxic 
effects of HAART. In this respect, preliminary work in our group has suggested that 
magnetic resonance spectroscopy (MRS) might detect lipid or protein peak signals in 
CSF that distinguish between HAART-induced neurotoxicity.  
 
Finally, further research into adjuvant treatments for HAND is needed in our 
population. Putative molecules have been suggested above, but all are problematic 
for reason of either cost or toxicity. Clinical studies using more cost-effective agents 
thought, might lead to proof-of-principle findings could in turn result in larger scale 
investigation of affordable molecules.  
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